Electrochemical D-lactate measurement for the diagnosis and prognosis of infectious diseases

Abstract

The present invention relates to an in vitro method for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance, and / or treatment control of an infectious disease, comprising: (a) providing a sample from a subject exhibiting clinical symptoms of infection and / or suspected of infection; (b) determining the level of D-lactate in the sample; (c) wherein the level of D-lactate indicates the presence of infection; and (d) determining the level of D-lactate in the sample by an electrochemical sensing system (biosensor). In an embodiment, the electrochemical sensing system comprises a potentiometric or amperometric sensor. Preferably, the electrochemical system comprises a D-lactate-binding molecule, preferably immobilized on a detection (working) electrode. In an embodiment, the detection electrode with the immobilized D-lactate-binding molecule comprises a (disposable) test strip for insertion into a portable reading device.

Description

[Technical Field]

[0001] (explanation) The present invention relates to an in vitro method for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance, and / or treatment control of an infectious disease, comprising: (a) providing a sample from a subject exhibiting clinical symptoms of infection and / or suspected of infection; (b) determining the level of D-lactate in the sample; (c) wherein the level of D-lactate indicates the presence of infection; and (d) determining the level of D-lactate in the sample by an electrochemical sensing system (biosensor). In an embodiment, the electrochemical sensing system comprises a potentiometric or amperometric sensor. Preferably, the electrochemical system comprises a D-lactate-binding molecule, preferably immobilized on a detection (working) electrode. In an embodiment, the detection electrode with the immobilized D-lactate-binding molecule comprises a (disposable) test strip for insertion into a portable reading device.

[0002] BACKGROUND OF THE INVENTION Prosthetic joint infection is a serious complication and is associated with significant mortality and morbidity (Non-Patent Document 1, Non-Patent Document 2). Timely and accurate diagnosis of infection is crucial to plan appropriate treatment, including arthroscopic or open surgical intervention. In prosthetic joints, low-level inflammation and subtle clinical symptoms can prevent the diagnosis of periprosthetic joint infection (PJI), which usually occurs months to years after arthroplasty.

[0003] Furthermore, infectious diseases in general pose significant health problems, and early and reliable diagnosis using rapid and consistent testing methods is urgently needed to improve therapeutic intervention in patients suspected of or diagnosed with infectious diseases.

[0004] Currently used synovial fluid diagnostic tests lack both high sensitivity and specificity for infection. Synovial fluid culture requires time for microbial growth and has limited sensitivity and specificity, especially in chronic, low-grade PJI (Non-Patent Documents 3-5). Synovial fluid leukocyte count and differential count (i.e., granulocyte percentage) are highly sensitive (Non-Patent Document 6), but may increase without infection within 6 weeks after surgery due to dislocation, periprosthetic fracture, or physiological inflammatory healing processes. Novel biomarkers in synovial fluid, such as alpha-defensins, leukocyte esterases, and calprotectin (Non-Patent Documents 7-9), are abundant in neutrophils and therefore cannot be used to diagnose PJI in patients with a sterile condition associated with high synovial fluid leukocyte counts.

[0005] Periprosthetic joint infection (PJI) is a serious complication after joint arthroplasty and is associated with significant morbidity and mortality. Accurate diagnosis of infection is crucial for planning appropriate treatment. In the era of orthopedic implants, such as endoprostheses, infection accounts for over 25% of revision surgeries (Non-Patent Document 26). Currently used synovial fluid diagnostic tests lack both high sensitivity and specificity for infection (Non-Patent Document 27). Synovial fluid cultures require time and have limited sensitivity and specificity in chronic, low-grade PJI (Non-Patent Documents 28-30). Low-level inflammation and subtle clinical symptoms can hinder the diagnosis of PJI, which can occur months to years after joint arthroplasty. Diagnosis is also challenging in the early postoperative period, when leukocyte counts, C-reactive protein, and clinical signs hinder a definitive diagnosis due to local tissue inflammation (Non-Patent Documents 31-33).

[0006] Several attempts have been made to investigate various biomarkers, such as α-2-macroglobulin, adenosine deaminase, procalcitonin, IL-1, IL-6, IL1β, and α-defensins, that may help distinguish PJI from sterile pathology (Non-patent literature 34-36).

[0007] D-lactate is a pathogen-specific metabolite primarily used in the diagnosis of bacterial infections in sterile body fluids (Non-Patent Document 10). Both the L- and D-rotamers of lactic acid are products of intracellular metabolism. However, mammalian cells contain only the enzyme L-lactate dehydrogenase (LDH) and can produce almost exclusively L-lactate. Serum concentrations of D-lactate in humans are extremely low, in the nanomolar to micromolar range, due to its role as a minor offshoot of glycolysis.

[0008] In contrast, bacterial species possess both D-LDH and L-LDH and therefore produce both D-lactate and L-lactate. As a result, the concentration of D-lactate increases to the millimolar range in bacterial infections (Non-Patent Documents 13, 14). Therefore, previous reports have suggested that measuring D-lactate in synovial fluid may be useful for the early diagnosis of septic arthritis, especially when compared with Gram staining and culture (Non-Patent Documents 11, 12).

[0009] In order to distinguish between infection and sterile inflammation, several studies were carried out in the 1990s to measure D-lactate concentrations in several primary sterile body fluids (Non-Patent Documents 40-42). D-lactate was shown to be a promising marker for the diagnosis of infection in various body fluids, such as bacterial meningitis and septic arthritis (Non-Patent Documents 41 and 43), including in patients receiving antibiotic therapy (Non-Patent Document 40).

[0010] However, established tests for diagnosing infections, particularly PJI, are associated with relatively low specificity. This was also found to be the case when measuring D-lactate concentrations in samples using established D-lactate assays, particularly spectrophotometric assays.

[0011] The trend in chemical and biological sensing is toward the use of multipurpose devices that require little or no user training. There are many options for transducers that convert signals from chemical recognition into electrical signals: optical, mass, thermal, and electrochemical sensors. Among chemical sensors, electrochemical sensors do not require external components such as bulky optical lenses or light sources, allowing for a high level of integration and often enabling low detection limits. Furthermore, the availability of a wide variety of off-the-shelf components makes electrochemical sensors particularly attractive in situations where portability and low cost are valued. These sensors are typically amperometric, impedimetric, or potentiometric and have been successfully used as chemical and biological sensors (57 and 58). Potentiometry therefore offers a powerful yet simple method for detecting several types of analytes, such as nucleic acids, antigens, and trace metals. Potential applications include point-of-care diagnostics and personalized medicine. Within potentiometric methods, transistor-based sensors offer a good alternative to disposable sensors at low cost and robustness. If such sensors could be cheaply and easily operated using measurement devices, the sensors could be utilized in a wide range of settings with minimal user training, particularly in remote and poorly resourced locations.

[0012] However, a suitable electrochemical sensor for D-lactate has not yet been developed. Moreover, it is not entirely clear whether an electrochemical sensor for D-lactate can provide reliable and reproducible results for determining D-lactate levels in samples that can be used in the context of in vitro methods for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance, and / or treatment control of infectious diseases.

[0013] Therefore, there is a need in the art for reliable in vitro methods for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance, and / or treatment control of infectious diseases that overcome the limitations of known methods. In particular, there is an urgent need for diagnostic methods with high sensitivity and specificity. Preferably, such methods should include electrochemical sensing systems that allow for simple test implementation while providing reproducible results. [Prior art documents] [Non-patent literature]

[0014] [Non-Patent Document 1] Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, DijkmansBA. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Annals of the rheumatic diseases. 1997;56(8):470-5. [Non-patent document 2] Geirsson AJ, Statkevicius S, Víkingsson A. Septic arthritis inIceland 1990-2002: increasing incidence due to iatrogenic infections. Annals of the rheumatic diseases. 2008;67(5):638-43. [Non-patent document 3] Corvec S, Portillo ME, Pasticci BM, Borens O, Trampuz A.Epidemiology and new developments in the diagnosis of prosthetic joint infection. Int J Artif Organs. 2012;35(10):923-34. [Non-patent document 4] Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. The New England journal of medicine. 2004;351(16):1645-54. [Non-Patent Document 5] Morgenstern C, Cabric S, Perka C, Trampuz A, Renz N. Synovial fluidmultiplex PCR is superior to culture for detection of low-virulent pathogenscausing periprosthetic joint infection. Diagnostic microbiology and infectiousdisease. 2018;90(2):115-9. [Non-patent document 6] Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. The American journal of medicine.2004;117(8):556-62. [Non-Patent Document 7] Renz N, Yermak K., Perka C., Trampuz A.Alpha defensin lateral flow test for diagnosis of periprosthetic jointinfection. Not a screening but a confirmatory test. . J Bone Joint Surg Am.2018(100(9)):742-50. [Non-patent document 8] Wouthuyzen-Bakker M, Ploegmakers JJW, Ottink K, Kampinga GA,Wagenmakers-Huizenga L, Jutte PC, et al. Synovial Calprotectin: An InexpensiveBiomarker to Exclude Chronic Prosthetic Joint Infection. J Arthroplasty.2018;33(4):1149-53.

Outdoor Tools9

Outdoor Tools 10

Outdoor Content11

Outdoor Tools 12

Outdoor Content13

Outdoor Tools 14

Outdoor Tools 15

Outdoor Content 16

Non-patent Document 17

Non-patent Document 18

Non-patent Document 19

Non-patent Document 20

Direct Environment21

Optional Website22

Optional Trademark23

Fashion 24

Wood 25

Table 26

Waterfall 27

Wood 28

Non-Patent Document 33

Non-Patent Document 34

Non-Patent Document 35

Direct Entries 36

Direct Entries 37

Direct Entries 38

Outdoor Track 39

Wood 40

Fashion 41

Wood 42

Wood 43

Direct Environment 44

Direct Environment 45

Direct Entries 46

Direct Entries 47

Non-licensed Document 48

Non-licensed Document 49

Non-licensed literature 50

Non-licensed Document 51

Non-licensed Document 52

Non-licensed Document 53

Non-Patent Document 54

Non-Patent Document 55

Non-Patent Document 56

[0015] In light of the prior art, the technical problem underlying the present invention is to provide improved in vitro methods for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance and / or treatment control of infectious diseases.

[0016] This problem is solved by the features of the independent claims. Preferred embodiments of the invention are provided by the dependent claims.

[0017] Thus, the present invention provides in a first aspect an in vitro method for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance and / or treatment control of an infectious disease, comprising: a. Preparing a sample from a subject exhibiting clinical symptoms of infection and / or suspected of infection; b. determining the level of D-lactate in the sample; c. where D-lactate levels indicate the presence of an infection; d. The method according to claim 1, wherein the level of D-lactate in the sample is determined by an electrochemical sensing system (biosensor).

[0018] The present invention is based on the unexpected discovery that measuring D-lactate by an electrochemical sensing system (biosensor) for determining the level of D-lactate in a sample according to the methods of the present invention results in a test with surprisingly high specificity compared to similar methods that use other means for determining the level of D-lactate, such as spectrophotometric measurement.

[0019] A major advantage of the method of the present invention is that the rate of false-positive events can be dramatically reduced compared to known tests using spectrophotometry. Surprisingly, it was found that the number of red blood cells and hemoglobin concentration in samples isolated from subjects showing clinical symptoms of infection and / or suspected of infection correlated with the level of D-lactate determined by spectrophotometry. This is likely because hemoglobin and D-lactate have interfering absorption wavelengths, i.e., 540 nm for hemoglobin and 570 nm for D-lactate. Therefore, blood contamination of the sample can lead to false-positive results in methods using spectrophotometry. In contrast, the electrochemical measurement used in the context of the present invention is not affected by the presence of red blood cells, and the false-positive rate and specificity of the test were found to be substantially improved compared to known methods. Importantly, the sensitivity of the method of the present invention is almost equal to the very high sensitivity of known methods using spectrophotometry of D-lactate, for example, for the diagnosis of PJI.

[0020] In a preferred embodiment, the electrochemical sensing system of the present invention is highly specific for detecting D-lactate, while the presence of L-lactate is not determined and does not affect the determination of D-lactate levels. Because L-lactate is not recognized by the D-lactate-specific electrochemical sensing system, the determination of D-lactate is completely independent of the presence of L-lactate.

[0021] In an embodiment of the present invention, the electrochemical sensing system comprises a potentiometric sensor, preferably a transistor-based potentiometric sensor.

[0022] In an embodiment, the electrochemical sensing system includes an ion-sensitive field effect transistor (ISFET), which is a potentiometric transistor-based potentiometric sensor.

[0023] In a further embodiment, the electrochemical sensing system includes an amperometric sensor.

[0024] In an embodiment, the sensor of the electrochemical sensing system is a potentiometric sensor. In an alternative embodiment, the sensor of the electrochemical sensing system is an amperometric sensor.

[0025] In an embodiment, the electrochemical sensing system includes a D-lactate binding molecule, such as D-LDH. The D-lactate binding molecule is present in an electrochemical cell of the electrochemical sensing system. The D-lactate binding molecule may be immobilized on a substrate of the electrochemical sensor, preferably on a detection electrode. In an embodiment of the present invention, the D-lactate binding molecule, such as D-LDH, may be provided in a solution, for example, in a buffer solution that is added to the electrochemical system for measurement, for example, by diluting a sample isolated from a patient therein.

[0026] When using a D-lactate-binding enzyme, the electrochemical cell and / or sample buffer of the invention may contain additional components required to carry out the chemical reaction catalyzed by the D-lactate-binding enzyme. In the case of D-LDH, the electrochemical system may include NAD.

[0027] In an embodiment of the invention, the electrochemical sensing system comprises a test strip or chip having suitable electrodes on its surface for performing electrochemical detection of D-lactate, preferably using a potentiometric or amperometric sensor. In an embodiment, the test strip or chip is disposable. In a further embodiment, the test strip or chip is reusable.

[0028] In a preferred embodiment, the test strip or chip of the electrochemical sensing system can be used by inserting it into a suitable reader, such as a handheld, compact, battery-powered reader. Handheld readers that are compact to allow for mobile use and use electrochemical test strips are known in the art for other analytes, such as glucose. Such devices are advantageous because they can provide immediate measurement and determination of the level of each analyte at the site of sample isolation. One example of such a device is the FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System.

[0029] In embodiments, the electrochemical sensing system preferably comprises a disposable test strip (chip) for electrochemically determining D-lactate levels, where the test strip comprises a detection electrode having an immobilized D-lactate binding molecule, and preferably also comprises a counter electrode and / or a reference electrode.

[0030] In embodiments, the measurement or determination of the D-lactate level is performed in a reader, preferably a handheld, battery-powered, compact reader. In embodiments, the disposable test strip can be placed in the reader, preferably a handheld, battery-powered, compact reader, to perform the D-lactate measurement. In embodiments, the reader is a benchtop reader rather than a handheld device.

[0031] In a preferred embodiment, the electrochemical sensing system is based on at least one of amperometry, potentiometry and field effect transistors.

[0032] In an embodiment, the electrochemical sensing system comprises a D-lactate binding molecule, preferably D-lactate dehydrogenase (D-LDH).

[0033] In an embodiment, the electrochemical sensing system comprises a sensing (working) electrode, preferably comprising a carbon or gold surface.

[0034] In a preferred embodiment, the D-lactate binding molecule, preferably D-LDH, is immobilized on a detection electrode.

[0035] According to a further embodiment of the present invention, the electrochemical sensing system comprises a detection (working) electrode, preferably comprising a carbon or gold surface, wherein a D-lactate binding molecule, preferably a D-lactate binding enzyme, more preferably D-lactate dehydrogenase (D-LDH), is immobilized on the surface of the detection (working) electrode.

[0036] In a preferred embodiment, the electrochemical sensing system includes a detection electrode comprising an immobilized lactate-binding molecule, hi a preferred embodiment, the lactate-binding molecule is D-LDH.

[0037] In embodiments, immobilization of D-lactate binding molecules, such as D-LDH, on the surface of the detection electrode is achieved by either adsorption, covalent binding, entrapment, encapsulation, cross-linking or thiol-gold interaction, preferably cross-linking or thiol-gold interaction.

[0038] It is preferable to use a D-lactate conjugating enzyme that catalyzes the chemical reaction that results in the production of NADH. Thus, the use of D-LDH is beneficial for the production of NAD + D-LDH enzymes are advantageous because they catalyze the reversible reaction of D-lactate to pyruvate and NADH in the presence of ATP. The D-LDH enzyme used to immobilize on the detection (working) electrode of the electrochemical sensing system may be commercially available D-LDH.

[0039] In embodiments, prior to binding of D-LDH onto the electrode surface, some modification of the electrode, e.g., coating with metal nanoparticles and / or other electrode design, e.g., graphene electrodes using in-house prepared chips, are preferably performed to be sensitive to the appropriate concentration range of D-lactate.

[0040] The chemical reaction catalyzed by D-LDH (D-lactate + NAD + →pyruvate + NADH) is released from the NADH. + + H + and 2e - It is decomposed into 2e - The (electrons) can be detected by a detection (working) electrode, which may be on the surface of the test strip (chip), and the electrochemical signal can be measured by a reader in contact with the detection electrode, such as a reader into which the test strip is inserted. Such a reader can be a small, handheld, battery-powered reader. In a preferred embodiment, such a reader uses amperometry. Additionally, it is possible to use a reader that uses potentiometry in the context of the present invention.

[0041] In the context of the present invention, the electrical signal can be recalculated to a molar concentration. For example, the electrochemical sensing system can be calibrated using a test sample having a known concentration of D-LDH in an appropriate medium, such as an appropriate buffer. The electrochemical sensing system may be pre-calibrated. In embodiments, the system of the present invention can include different sensing modes corresponding to different sample conditions, for example, corresponding to the measurement of different body fluids.

[0042] In the context of the present invention, immobilization of D-LDH on the surface of the detection electrode can be achieved either by adsorption, covalent binding, entrapment, encapsulation, or preferably cross-linking, or via thiol-gold interactions. In embodiments, other immobilization techniques known to those skilled in the art can be used.

[0043] For adsorption, enzymes can be attached to the electrode surface through weak interactions to avoid enzyme denaturation. This has been particularly successful if the electrode surface has first been ionized by plasma or acid treatment, by covalent modification of the surface such as amination, or by deposition of ionic polymers either by electropolymerization or drop-casting / spin-coating.

[0044] Cross-linking is a frequently used method in which a dialdehyde (glutaraldehyde) reacts with the amine groups of the enzyme and the amine groups on the aminated surface. Another method is the thiol-gold interaction, in which a thiol group is added to the enzyme (or uses a cysteine ​​in the enzyme) and thiolation of the gold allows the enzyme to be linked to the surface.

[0045] Encapsulation is another very common immobilization method known to those skilled in the art. Encapsulation methods involve electrochemical polymerization or crosslinking of a thin network of polymers on top of the enzyme on the surface. In this way, the enzyme cannot leave the surface but still provides access for substrate molecules for the enzymatic reaction.

[0046] In embodiments, the detection electrode is preferably modified prior to immobilization of the D-lactate binding molecule in order to fine-tune the detection performance and increase and / or adjust the sensitivity of the biosensor in the appropriate concentration range of D-lactate.

[0047] In an embodiment, an electrochemical sensing system comprises a sensing electrode coated with metal nanoparticles.

[0048] In embodiments, an electrochemical sensing system includes a sensing electrode that includes or consists of graphene.

[0049] Additionally, in embodiments, the system allows for the parallel determination of D-lactate levels in more than one sample. A major advantage of the present invention is that it allows for multiplexing of multiple samples that can be measured in parallel.

[0050] In an embodiment, the infection of the present invention is a microbial, bacterial and / or fungal infection, preferably having at least one infectious agent selected from the group consisting of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus species, Enterococcus species, anaerobes, gram-negative bacteria and Candida species.

[0051] In the context of the present invention, the infection may be a joint infection, a periprosthetic joint infection (PJI), meningitis, peritonitis, a pleural cavity infection, a pericardial cavity infection and / or a bloodstream infection.

[0052] The present invention is particularly preferably used for the diagnosis of meningitis. Surprisingly, it has been observed that electrochemical sensing of D-lactate in cerebrospinal fluid is particularly advantageous compared to other D-lactate detection methods, since cerebrospinal fluid samples are frequently contaminated with blood during the sample isolation procedure.

[0053] Furthermore, the present invention is particularly useful for measuring D-lactate in blood samples, which cannot be used for spectrophotometric measurement due to the large amount of red blood cells and hemoglobin. Therefore, serum or plasma samples must be obtained from the blood or blood sample to detect circulating D-lactate. The present invention allows for the determination of D-lactate levels in blood samples immediately after isolation, eliminating the need for a serum or plasma production step.

[0054] If the infection is a joint infection, synovial fluid may be used as the sample. In this regard, measuring D-lactate using an electrochemical sensing system is particularly advantageous compared to spectrophotometric measurement, since joint aspirates are often contaminated with blood. Furthermore, synovial fluid in artificial joints is often contaminated with blood, especially after surgery. Therefore, the presence of red blood cells (RBCs) or hemoglobin from lysed RBCs contaminates samples obtained from blood-containing samples, making them prone to erroneous results when measured by spectrophotometry.

[0055] If the infection is peritonitis, ascites fluid isolated with or without a peritoneal catheter may be used as the sample. If the infection is a pleural cavity infection, pleural fluid may be used as the sample.

[0056] If the infection is a pericardial space infection or pericarditis, pericardial fluid may be used as the sample.

[0057] In the case of bloodstream infection or sepsis, blood or blood-derived material may be used as the sample, where the blood may be isolated with or without an intravascular catheter.

[0058] In embodiments, an increased level of D-lactate as determined by the electrochemical sensing system in the sample compared to a suitable control, such as a sample from a healthy subject, indicates the presence of an infection.

[0059] According to a further embodiment of the present invention, a current or voltage measurement by the electrochemical sensing system corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater indicates the presence of an infection.

[0060] In a further embodiment, a current or voltage measurement by the electrochemical sensing system corresponding to a level of D-lactate in the sample of 0.4 mmol / L or greater, preferably 0.5 mmol / L or greater, more preferably 1.0 mmol / L or greater, and most preferably 1.2 mmol / L or greater indicates the presence of an infection.

[0061] Furthermore, the method of the present invention may be characterized by the fact that a current or voltage measurement by the electrochemical sensing system corresponding to a level of D-lactate in said sample of 0.5 mmol / L or greater, preferably 1.0 mmol / L or greater, more preferably 1.2 mmol / L or greater, indicates the need to initiate or change antibiotic treatment.

[0062] Further, possible threshold levels of the present invention include 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.05, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mmol / L. A range encompassing any combination of the values ​​disclosed herein as limits is considered to represent a disclosed embodiment of the present invention.

[0063] The threshold levels disclosed herein refer to measurements of D-lactate in synovial fluid samples obtained from patients, preferably using a D-Lactam™ diagnostic kit provided by Sivital, Vitebsk (Belarus), obtained from VL-Diagnostics (Leipzig) and used in the context of the present examples. Thus, the values ​​disclosed herein may vary to some extent depending on the detection / measurement system or kit used, and specific values ​​disclosed herein are also intended to read off corresponding values ​​determined by other measurement systems or kits. For example, a comparison of spectrophotometric D-lactate measurements using two different test kits (provided by Sigma-Aldrich (St. Louis, MO, USA) and VL-Diagnostics (Leipzig, Germany) respectively) showed that the specifically determined cutoff value also depends on the test kit and the method for determining D-lactate levels (Karbysheva et al. Performance of synovial fluid D-lactate for the diagnosis of acute and chronic / low-grade PJI; Abstract at EFORT Conference 2018, Barcelona, ​​Spain).

[0064] Thus, in embodiments of the present invention, cutoff values ​​used in the context of electrochemical measurements, such as amperometry or potentiometry, may correspond to different D-lactate concentrations compared to cutoff concentrations of D-lactate determined by spectrophotometric measurements using a particular test kit.

[0065] The readout of an electrochemical measurement involves detecting a current and a voltage. The detected value depends on the configuration of the electrochemical sensing system. Modifications to various components of the system or method of the present invention (such as the sample) will affect the detected current or voltage, respectively. Therefore, it is not possible to provide a general cutoff value or threshold value for an electrochemical measurement. However, in embodiments, the electrochemical sensing system of the present invention requires calibration with a reference sample having a predetermined, known D-lactate concentration, so that any given electrochemical system can be provided suitable for determining a D-lactate cutoff value / threshold level corresponding to a particular D-lactate concentration shown to be indicative of an infection, and optionally, the initiation of antibiotic treatment for a certain sample.

[0066] In a preferred embodiment of the present invention, the sample is diluted in a phosphate buffer. In embodiments, the pH of the phosphate buffer is 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. Ranges encompassing any combination of the values ​​disclosed as limits are disclosed embodiments of the present invention. Buffers or sample solutions having a pH of about 7.5 to 9.5 are preferred, with a pH of about 8 to 9 being more preferred, and a pH of 8.5 being particularly preferred. D-lactate binding molecules, particularly D-LDH, have been shown to work very effectively in detecting D-lactate in the context of an electrochemical sensing system at pH 8.5. A possible buffer for diluting samples, such as body fluids like synovial fluid, is a phosphate buffer.

[0067] In embodiments, the electrochemical sensing system is calibrated using one or more calibration samples of defined D-lactate concentrations before determining the level of D-lactate in the sample. For example, commercially available D-lactate diluted to a known concentration in an appropriate buffer solution, which may be the same as the buffer solution used to determine the D-lactate level in the sample, can be used to determine the voltage corresponding to a specific concentration of D-lactate in the sample.

[0068] In certain embodiments including a potentiometric sensor, a voltage of about 85 mV corresponds to a D-lactate level of 1.2 mmol / L and can indicate the presence of an infection. Voltage measurements in electrochemical sensing systems can vary depending on the exact setup of the system and the type of sensor.

[0069] In certain embodiments including an amperometric sensor, a current of about 422 nA corresponds to a D-lactate level of about 1.2 mmol / L and can indicate the presence of an infection. The amperometric measurements of an electrochemical sensing system can vary depending on the exact setup of the system and the type of sensor.

[0070] 2. The in vitro method of any one of the preceding clauses, wherein a current or voltage measurement by an electrochemical sensing system corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater indicates a need for initiation or modification of antibiotic treatment.

[0071] However, a current or voltage corresponding to a D-lactate level of 1.2 mmol / L may represent a preferred cut-off value in the context of the present invention, particularly for synovial fluid samples that may be used to detect joint infections.

[0072] Preferably, in the context of the present invention, the level of D-lactate determined by an electrochemical sensing system is not affected by the number of red blood cells and / or hemoglobin present in the sample.

[0073] According to another embodiment of the present invention, the sample is selected from the group consisting of a body fluid sample, a homogenized tissue sample, a blood sample, a serum sample, a plasma sample, a urine sample, a joint aspirate, a synovial fluid sample, a peritoneal fluid sample, a pleural fluid sample, a pericardial fluid sample, and / or a cerebrospinal fluid sample.

[0074] In a further aspect, the present invention relates to an electrochemical sensing system (biosensor) for measuring the level of D-lactate in a sample. The electrochemical sensing system of the present invention is a system described in the context of the methods and kits of the present invention.

[0075] In another aspect, the present invention provides a kit for carrying out the method of the present invention, comprising: an electrochemical sensing system for determining the level of D-lactate in a sample; reference data, such as a reference level, preferably corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater, wherein the reference data is optionally stored on a computer-readable medium and / or used in the form of computer-executable code configured to compare the determined level of D-lactate with the reference data; and Optionally, a reagent for calibrating the electrochemical sensing system. The present invention also relates to a kit comprising:

[0076] The present invention also provides a kit for carrying out the method of the present invention, comprising: an electrochemical sensing system for determining the level of D-lactate in a sample, preferably comprising a test strip (chip) having suitable electrodes or transistor-based sensors on its surface for electrochemical detection, wherein the electrochemical signal is measured by a reader, preferably a battery-powered, handheld, compact reader; reference data, such as a reference level, preferably corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater, wherein the reference data is optionally stored on a computer-readable medium and / or used in the form of computer-executable code configured to compare the determined level of D-lactate with the reference data; and Optionally, a reagent for calibrating the electrochemical sensing system. The present invention also relates to a kit comprising:

[0077] The present invention further provides a kit for carrying out the method of the present invention, comprising: 1. An electrochemical sensing system for determining the level of D-lactate in a sample, wherein the electrochemical sensing system preferably comprises: a test strip (chip) for electrochemically determining iD-lactate levels, said test strip comprising a detection electrode having an immobilized D-lactate binding molecule, and preferably further comprising a counter electrode and / or a reference electrode; ii. optionally a handheld, compact reader for inserting the test strip and performing the D-lactate measurement; reference data, such as a reference level, preferably corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater, wherein the reference data is optionally stored on a computer-readable medium and / or used in the form of computer-executable code configured to compare the determined level of D-lactate with the reference data; and Optionally, a reagent for calibrating the electrochemical sensing system. The present invention relates to a kit comprising:

[0078] The kits of the present invention may also include instructions for use. The cutoff values ​​provided by the kit may vary depending on the infectious disease and the sample used to practice the method of the present invention. The kit may provide a list of appropriate cutoff values ​​for a list of infectious diseases and / or samples used.

[0079] Reagents for calibrating the electrochemical system can include D-lactate and an appropriate buffer solution to generate a suitable calibration sample. Such samples can be provided prepared, or the base materials and reagents for generating such samples can be provided with the kit, allowing users to generate a custom calibration sample for their particular application of the kit.

[0080] In a further aspect, the present invention relates to an electrochemical sensing system (biosensor) for determining the level of D-lactate in a sample. Embodiments of the electrochemical sensing system of the present invention are described in the context of the methods and kits of the present invention. In a preferred embodiment, the electrochemical sensing system for determining the level of D-lactate in a sample comprises D-LDH as a D-lactate recognition component immobilized on a test strip for insertion into a handheld reader.

[0081] In embodiments, the electrochemical sensing system of the present invention comprises a potentiometric sensor and / or an amperometric sensor. The system preferably comprises a detection (working) electrode having a D-lactate binding molecule, preferably D-LDH, immobilized on the electrode surface. In a preferred embodiment, the electrochemical sensing system comprises a (preferably disposable) test strip containing the detection electrode having the immobilized D-lactate binding molecule and preferably also a counter electrode and / or a reference electrode. In embodiments, the electrochemical sensing system also comprises a reader, preferably a portable, handheld reader suitable for inserting the test strip and measuring D-lactate in a sample.

[0082] All features disclosed in the context of the methods of the invention are also disclosed herein in the context of the kits and electrochemical sensing systems of the invention, and vice versa. Thus, features of embodiments of the methods of the invention may also be features of embodiments of the kits and electrochemical sensing systems of the invention, and vice versa.

[0083] (Detailed Description of the Invention) The present invention relates to an in vitro method for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance and / or treatment control of an infectious disease, comprising: (a) providing a sample from a subject exhibiting symptoms of and / or suspected of having an infectious disease; (b) determining the level of D-lactate in the sample; (c) wherein the level of D-lactate indicates the presence of an infectious disease; and (d) wherein the level of D-lactate in the sample is determined by an electrochemical sensing system (biosensor).

[0084] As used herein, "diagnosis" in the context of the present invention relates to the recognition and (early) detection of a subject's clinical condition related to an infectious disease. Also, the assessment of the severity of an infectious disease may be encompassed by the term "diagnosis". "Prognosis" relates to the prediction of the outcome or particular risk of a subject based on an infectious disease. This may also include the determination of the likelihood of recovery or the likelihood of an adverse outcome for said subject.

[0085] The term "risk assessment" and potentially subsequent patient stratification relates to grouping subjects into different risk groups depending on the subject's prognosis. Risk assessment also relates to stratification for applying preventive and / or therapeutic measures. Furthermore, the methods of the present invention may be used for therapeutic stratification, where the term "therapeutic stratification" particularly relates to grouping or classifying patients into different groups, such as risk groups or treatment groups, that receive specific different therapeutic measures depending on the classification. The term "therapeutic stratification" also relates to grouping or classifying patients with infectious diseases or symptoms of infectious diseases into groups that do not need to receive specific therapeutic measures, such as antibiotic treatment.

[0086] The method of the present invention can also be used for monitoring. "Monitoring" in the context of the method of the present invention related to infectious diseases refers to tracking already diagnosed infectious diseases, disorders, complications or risks, for example, analyzing the progression of a disease or the disease progression of a critical patient or the effect of a specific treatment or therapy on an infectious disease in a patient. The terms "therapeutic monitoring" and "therapeutic control" in the context of the present invention refer to monitoring and / or adjusting the therapeutic treatment of the subject, for example, by obtaining feedback on the effectiveness of the treatment. As used herein, the term "therapeutic guidance" refers to the application of a specific treatment, therapeutic action or medical intervention based on the level of D-lactate determined in the context of the present invention. This includes adjusting or ceasing treatment.

[0087] The term infectious disease relates to and includes all diseases or disorders associated with and / or caused by infection, particularly bacterial, viral, and / or fungal infections. As used herein, "infection" relates to a pathological process caused by the infiltration of normally sterile tissue or body fluids by a pathogenic or potentially pathogenic agent / pathogen, organism, and / or microorganism, and preferably relates to bacterial, viral, fungal, and / or parasitic infection(s). Thus, an infection may be a bacterial infection, a viral infection, and / or a fungal infection. An infection may be a local or systemic infection. For the purposes of the present invention, a viral infection may be considered an infection by a microorganism.

[0088] Nosocomial infections are included in this invention. Nosocomial infections are also called hospital-acquired infections or healthcare-associated infections because they can be acquired in hospitals, nursing homes, rehabilitation facilities, outpatient clinics, or other clinical or medical settings. Nosocomial infections can spread to susceptible patients in clinical settings by various means. Medical staff can spread infections through contaminated equipment, bed linen, or air droplets. Infections can originate from the external environment, another infected patient, potentially infected staff, or, in some cases, an undetermined source. In some cases, microorganisms originate from the patient's own skin microbiota and become opportunistic after surgery or other procedures that compromise the protective skin barrier. Although a patient may have contracted the infection through their own skin, the infection is still considered nosocomial because it develops in a healthcare setting.

[0089] In embodiments, a subject suffering from infection may be simultaneously affected by two or more infectious agents.For example, a subject may suffer from bacterial infection and viral infection; viral infection and fungal infection; bacterial and fungal infection; and bacterial infection, fungal infection and viral infection, or may potentially suffer from a superinfection, for example, a mixed infection comprising one or more of the infectious agents listed herein, including one or more viral infections and / or one or more fungal infections, as well as one or more bacterial infections.

[0090] In the context of the present invention, the infection is preferably associated with a bacterial and / or fungal infection, preferably with at least one infectious agent selected from the group consisting of Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus species, Enterococcus species, anaerobes, gram-negative bacteria and Candida species.

[0091] In one embodiment, the infection to be detected or tested for is Bordetella spp., such as Bordetella pertussis, Borrelia spp., such as Borrelia burgdorferi, Brucella spp., such as Brucella abortus, Brucella canis, Brucella melitensis or Brucella suis, Campylobacter spp., such as Campylobacter jejuni, Chlamydia spp. and Chlamydophila spp., such as Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium species such as Clostridium botulinum, Clostridium difficile, Clostridium perfringens, and Clostridium tetani; Corynebacterium species such as Corynebacterium diphtheriae; Enterococcus species such as Enterococcus faecalis and Enterococcus faecium; Escherichia species such as Escherichia coli; Francisella species such as Francisella tularensis; Haemophilus influenzae Haemophilus species such as Helicobacter pylori, Helicobacter species such as Legionella pneumophila, Leptospira interrogans,Leptospira species such as L. interrogans, Listeria species such as Listeria monocytogenes, Mycobacterium species such as Mycobacterium leprae, Mycobacterium tuberculosis, and Mycobacterium ulcerans, Mycoplasma species such as Mycoplasma pneumonia, Neisseria species such as Neisseria gonorrhoeae and Neisseria meningitides, Pseudomonas species such as Pseudomonas aeruginosa, Rickettsia species such as Rickettsia rickettsia, Salmonella typhi, Salmonella bacteria such as Salmonella typhi and Salmonella typhimurium, Shigella genus such as Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes, Treponema pallidum, Treponema species such as Vibrio pallidum, Vibrio species such as Vibrio cholera, Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosisThe host may be selected from species of the genus Yersinia, such as Yersinia pseudotuberculosis.

[0092] Pathogenic fungi are fungi that cause disease in humans or other organisms. Candida species are important human pathogens, best known for causing opportunistic infections in immunocompromised hosts (e.g., transplant recipients, AIDS patients, and cancer patients). Infections can be difficult to treat and very serious: 30–40% of systemic infections are fatal. Aspergillosis is another potential fungal pathogen. Aspergillus can cause disease in three major ways: by producing mycotoxins, by eliciting an allergen response, and by causing localized or systemic infections. In the latter two categories, the immune status of the host is crucial. The most common pathogenic species are Aspergillus fumigatus and Aspergillus flavus. Aspergillus flavus produces aflatoxin, which is both a toxin and a carcinogen and can contaminate food. Aspergillus fumigatus and Aspergillus clavatus can cause disease. Cryptococcus neoformans can cause disease in humans. Cryptococcus neoformans is a major human and animal pathogen. Cryptococcus laurentii and Cryptococcus albidus are known to occasionally cause moderate to severe disease in immunocompromised human patients. Cryptococcus gattii is endemic to tropical regions of Africa and Australia and can cause disease. Histoplasma capsulatum can cause histoplasmosis in humans, dogs, and cats. Pneumocystis jirovecii (or Pneumocystis carinii) can cause a type of pneumonia in premature infants, the elderly, and people with weakened immune systems, such as those with AIDS.Stachybotrys chartarum, or "black mold," can cause respiratory damage and severe headaches.

[0093] In one embodiment, the infection to be detected or tested for is Acinetobacter baumannii, Klebsiella pneumoniae, Acinetobacter lwoffii, Listeria monocytogenes, Aeromonas caviae, Morganella morganii, Aeromonas hydrophila, Neisseria gonorrhoeae, Aspergillus flavus, Neisseria meningitidis, Aspergillus nidulans, nidulans, Pasteurella multocida, Aspergillus niger, Pasteurella pneumotropica, Aspergillus terreus, Propionibacterium acnes, Bacillus anthracis, Proteus mirabilis, Bacillus cereus, Providencia rettgeri, Bacillus subtilis, Pseudomonas aeruginosa aeruginosa, Bacteroides fragilis, Salmonella choleraesuis, Brucella melitensis, Serratia liquefaciens, Burkholderia cepaciacepacia, Serratia marcescens, Candida albicans, Staphylococcus aureus, Candida dubliniensis, Staphylococcus epidermidis, Candida glabrata, Staphylococcus haemolyticus, Candida krusei, Staphylococcus hominis, Candida parapsilosis, Staphylococcus saccharolyticus saccharolyticus, Candida tropicalis, Staphylococcus warneri, Capnocytophaga canimorsus, Stenotrophomonas maltophilia, Citrobacter braakii, Streptococcus agalactiae, Citrobacter freundii, Streptococcus anginosus, Clostridium perfringens, Streptococcus bovis, Corynebacterium jeikeium jeikeium, Streptococcus constellatus, Enterobacter aerogenes, Streptococcus dysgalactiaedysgalactiae, Enterobacter cloacae, Streptococcus mutans, Enterobacter sakazakii, Streptococcus pneumoniae, Enterococcus faecalis, Streptococcus pyogenes, Enterococcus faecium, Streptococcus salivarius, Escherichia coli coli, Streptococcus sanguinis, Shigella sp., Streptococcus suis, Gemella haemolysans, Vibrio vulnificus, Gemella morbillorum, Yersinia enterocolitica, Haemophilus influenzae, Yersinia pestis, Kingella kingae, Yersinia pseudotuberculosis, and Klebsiella oxytoca.

[0094] In an embodiment of the invention, the infection is a joint infection, a periprosthetic joint infection (PJI), a central nervous system infection, meningitis, peritonitis, a pleural cavity infection, a pericardial cavity infection and / or a bloodstream infection.

[0095] In the context of embodiments of the present invention, the sample preferably corresponds to a body fluid that has been in contact with a tissue or organ suspected to be infected, for example in the case of a CNS infection or meningitis, a CSF sample may preferably be used.

[0096] Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord, collectively known as the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, vomiting, and intolerance to light and loud noises. Young children often exhibit only nonspecific symptoms, such as irritability, drowsiness, and loss of appetite. The presence of a rash may indicate a specific cause of meningitis; for example, meningitis caused by Neisseria meningitidis may be accompanied by a characteristic rash. Inflammation can be caused by infection with viruses, bacteria, or other microorganisms, but is less likely to occur with certain drugs. Because meningitis can be life-threatening due to its proximity to the brain and spinal cord, the condition is classified as a medical emergency. A lumbar puncture, in which a needle is inserted into the spinal canal to obtain a sample of cerebrospinal fluid (CSF), can diagnose or rule out meningitis.

[0097] As used herein, the term "bloodborne infection" may include systemic bloodstream infection, sepsis, severe sepsis and / or septic shock.

[0098] Joint infection, also known as septic arthritis or infectious arthritis, is the invasion of a joint by an infectious agent, resulting in joint inflammation. Symptoms typically include redness, heat, and pain in a single joint, along with decreased ability to move the joint. Onset is usually rapid. Other symptoms include fever, weakness, and headache. Occasionally, multiple joints may be involved. Causes include bacteria, viruses, fungi, and parasites. Risk factors include an artificial / prosthetic joint, prior arthritis, diabetes, and poor immune function. Joint infection is most commonly transmitted through the bloodstream, but can also occur through trauma or periarticular infection. Diagnosis is generally based on aspirating and culturing synovial fluid. Initial treatment typically includes antibiotics such as vancomycin, ceftriaxone, or ceftazidime. Surgery may also be performed to clean the joint. If not treated early, long-term joint problems can occur. Septic arthritis occurs in approximately 5 out of 100,000 people each year. It is more common in older people. With treatment, about 15% of people die, but without treatment, 66% die.

[0099] In embodiments of the present invention, the methods of the present invention may include a treatment step if the electrochemical measurement of D-lactate indicates the presence of an infection, in which one or more of the treatments disclosed herein may be administered to the respective patient.

[0100] In the context of the present invention, the term "medical treatment" or "treatment" includes various treatments and therapeutic strategies, in particular treatments known to those skilled in the art for each diagnosed infection. In the context of the present invention, a treatment may include antibiotic treatment, for example, intravenous antibiotics, oral antibiotics, or topical antibiotics. A medical treatment of the present invention may be an antibiotic treatment, in which one or more "antibiotics" or "antibiotic preparations" may be administered once an infection has been diagnosed or symptoms of an infection have been determined.

[0101] Antibiotics or antibiotic preparations according to the present invention also potentially encompass antifungal or antiviral compounds used to treat diagnosed infections or sepsis. Commonly applied antibiotic preparations in the treatment of any given infection that may be used in the context of the present invention, divided into classes of pathogens, include:

[0102] Applicable to Gram-positive bacteria: Penicillins (ampicillin, amoxicillin), penicillinase-resistant (dicloxacillin, oxacillin), cephalosporins (1st and 2nd generation), macrolides (erythromycin, clarithromycin, azithromycin), quinolones (gatifloxacin, moxifloxacin, levofloxacin), vancomycin, sulfonamides / trimethoprim, clindamycin, tetracyclines, chloramphenicol, linezolid, and synacid. Gram-negative bacteria: broad-spectrum penicillins (ticarcillin, clavulanic acid, piperacillin, tazobactam), cephalosporins (second, third, and fourth generation), aminoglycosides, macrolides, azithromycin, quinolones (ciprofloxacin), monobactams (azetreonam), sulfonamides / trimethoprim, carbapenems (imipenem), and chloramphenicol. Pseudomonas: ciprofloxacin, aminoglycosides, some third-generation cephalosporins, fourth-generation cephalosporins, broad-spectrum penicillins, and carbapenems.

[0103] Fungal Treatment: Allylamines (positive: allylamines), amphotericin B, fluconazole and other azoles, itraconazole, voriconazole, posaconazole, ravuconazole, echinocandins, flucytosine, sordarin, chitin synthase inhibitors, topoisomerase inhibitors, lipopeptides, pradimicin, liposomal nystatin, voriconazole, echinocanidine, imidazoles, triazoles, thiazoles, polyenes.

[0104] Antiviral therapy: abacavir, acyclovir, activated caspase oligomerizer, adefovir, amantadine, amprenavir (agenase), ampligen, arbidol, atazanavir, atripla, baravir, cidofovir, combivir, dolutegravir, darunavir, delavirdine, didanosine, double-stranded RNA, dacosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoli antiretroviral drugs, famiciclovir, fixed-dose combination (antiretroviral drugs), fomivirsen, fosamprenavir, foscarnet, phosphonet, fusion inhibitors, ganciclovir, ibacitabine, Immunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, interferon type III, interferon type II, interferon type I, interferon, lamivudine, lopinavir, loviride, mammary gland Raviroc, moroxydine, methisazone, morpholino, nelfinavir, nevirapine, nexavir, nitazoxanide, nucleoside derivatives, novir, oseltamivir (Tamiflu), peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitors (pharmacology), raltegravir, reverse transcriptase inhibitors, ribavirin, ribozyme, rifampicin, rimantadine, ritonavir, RNase H, protease inhibitors, pyrimidines, saquinavir, sofosbuvir, stavudine, synergistic enhancers (antiretrovirals), telaprevir, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, Truvada, valacyclovir (Valtrex), valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir (Relenza), zidovudine.

[0105] Additionally, antibiotic preparations include bacteriophages for the treatment of bacterial infections, and synthetic antimicrobial peptides or iron antagonists / chelators may be used. Also, therapeutic antibodies or antagonists against pathogenic structures, such as anti-VAP antibodies, anti-resistant clonal vaccination, and administration of immune cells, such as in vitro primed or modulated T-effector cells, are antibiotic preparations that represent treatment options in the context of the present invention. Further antibiotic preparations / treatments or therapeutic strategies for infection or prevention of new infections include the use of antiseptics, decontamination products, anti-pathogenic agents such as liposomes, hygiene, wound care, and surgery.

[0106] It is also possible to combine several of the above antibiotic agents or treatment strategies.

[0107] In embodiments, the invention encompasses the administration of an appropriate antibiotic for treatment based on information obtained by the methods described herein.

[0108] The methods of the present invention are particularly advantageous because it has been found that electrochemical D-lactate measurement of patient samples allows for a diagnostic test with very high specificity and sensitivity compared to known methods that are suboptimal in at least one of these test properties.

[0109] Sensitivity and specificity are statistical measures of the performance of binary classification tests, also known in statistics as classification functions, that are widely used in medicine. Sensitivity (also called true positive rate, recall, or probability of detection in some fields) measures the proportion of actual positives that are correctly identified as such (e.g., the proportion of sick people correctly identified as having the condition). Specificity (also called true negative rate) measures the proportion of actual negatives that are correctly identified as such (e.g., the proportion of healthy people correctly identified as not having the condition). For many tests, including diagnostic medical tests, sensitivity is the degree to which actual positives are not overlooked (so there are few false negatives), and specificity is the degree to which actual negatives are classified as such (so there are few false positives). Thus, a highly sensitive test will rarely miss actual positives (e.g., indicating "nothing bad" when something bad is present), and a highly specific test will rarely record positive classifications for things that are not the target of the test (e.g., finding one bacterial species and mistaking it for another closely related one that is the true target).

[0110] As used herein, the sensitivity and specificity of a diagnostic and / or prognostic test depend not only on the analytical "quality" of the test, but also on the definition of what constitutes an abnormal result. In practice, a receiver operating characteristic curve (ROC curve) is typically calculated by plotting the value of a variable versus its relative frequency in "normal" (i.e., apparently healthy individuals without infection) and a "disease" population, e.g., subjects with infection). In the present case, the distributions of D-lactate levels for subjects with and without disease / condition will likely overlap. In such conditions, the test will not absolutely distinguish normal from disease with 100% accuracy, and the overlapping area may indicate where the test cannot distinguish normal from disease. A threshold is selected, below which the test is considered abnormal and above which the test is considered normal, or below or above which the test indicates a particular condition, e.g., infection. The area under the ROC curve is a measure of the probability that the recognized measurement allows for correct identification of the condition. The ROC curve can be used even when the test result does not necessarily provide an accurate numerical value. As long as the results can be ranked, ROC curves can be created. For example, the test results of "disease" samples can be ranked by degree (for example, 1 = low, 2 = normal, 3 = high). This ranking is correlated with the results of "normal" population, and an ROC curve is created. These methods are well known in the art, see, for example, Hanley et al. 1982. Radiology 143: 29-36. Preferably, the threshold value is selected to provide an ROC curve area greater than about 0.5, more preferably greater than about 0.7, even more preferably greater than about 0.8, even more preferably greater than about 0.85, and most preferably greater than about 0.9. The term "about" in this context refers to + / - 5% of a given measurement value.

[0111] The horizontal axis of the ROC curve represents (1-specificity), which increases with the rate of false positives. The vertical axis of the curve represents sensitivity, which increases with the true positive rate. Therefore, for a particular cutoff selected, the value of (1-specificity) may be determined, and the corresponding sensitivity may be obtained. The area under the ROC curve is a measure of the probability that the measured marker level allows for the correct identification of a disease or condition. Therefore, the area under the ROC curve can be used to determine the effectiveness of the test.

[0112] As used herein, a "patient" or "subject" may be a vertebrate. In the context of the present invention, the term "subject" includes both humans and animals, particularly mammals, as well as other organisms.

[0113] In the sense of the present invention, a patient showing symptoms of an infectious disease is a subject who exhibits one or more of the following symptoms, but is not limited to: fever, diarrhea, fatigue, muscle pain, cough, and in the case of an animal bite, difficulty breathing, severe headache accompanied by fever, rash or swelling, unexplained or prolonged fever, or visual problems. Other symptoms may include fever and chills, very low body temperature, oliguria, rapid pulse, shortness of breath, nausea, and vomiting. In an embodiment, the symptoms of an infectious disease are fever, diarrhea, fatigue, muscle pain, rapid pulse, shortness of breath, nausea, vomiting, and / or cough.

[0114] As used herein, the term "sample" refers to a biological sample obtained or isolated from a patient or subject. As used herein, "sample" may refer to, for example, a body fluid sample, a homogenized tissue sample, a blood sample, a serum sample, a plasma sample, a urine sample, a joint aspirate, a synovial fluid sample, an ascites sample, a peritoneal fluid sample, a pleural fluid sample, a pericardial fluid sample, and / or a cerebrospinal fluid sample. The sample is preferably isolated or obtained for the purpose of diagnosis, prognosis, or evaluation of a subject of interest, such as a patient. The sample of the present invention may be, for example, a sample of a body fluid, such as blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, pleural effusion, cells, a cell extract, a tissue sample, a tissue biopsy, a stool sample, etc. In particular, the sample is blood, plasma, serum, or urine.

[0115] As used herein, a blood sample is a whole blood sample that has not been treated to alter its composition. In particular, a blood sample contains blood cells. Serum and plasma samples are produced from blood. "Plasma" in the context of the present invention is the substantially cell-free supernatant of blood containing an anticoagulant obtained after centrifugation. Exemplary anticoagulants include calcium ion-binding compounds such as EDTA or citrate and thrombin inhibitors such as heparate or hirudin. Cell-free plasma can be obtained by centrifugation of anticoagulated blood (e.g., citrated, EDTA, or heparinized blood), for example, at 2000-3000 g for at least 15 minutes. "Serum" in the context of the present invention is the liquid fraction of whole blood collected after clotting. When the clotted blood (clot) is centrifuged, serum is obtained as the supernatant.

[0116] Cerebrospinal fluid (CSF) samples are collected by puncturing a body space filled with CSF, also known as liquor. CSF is collected primarily by lumbar puncture of the central canal of the spinal cord. Cerebrospinal fluid (CSF) is a colorless, clear fluid found in the brain and spinal cord. It is produced by specialized ependymal cells in the choroid plexus of the ventricles and absorbed in arachnoid granulations. In adults, approximately 125 mL of CSF is present at any one time, and approximately 500 mL is produced daily. CSF acts as a cushion or buffer, providing essential mechanical and immunological protection to the brain within the skull. CSF also plays an important role in the cerebral autoregulation of cerebral blood flow. CSF occupies the subarachnoid space (between the arachnoid and pia mater) and the ventricular system surrounding and within the brain and spinal cord. It fills the ventricles, cisterns, and sulci, as well as the central canal of the spinal cord. There is also a connection from the subarachnoid space to the bony labyrinth of the inner ear via the perilymphatic duct, which connects the perilymph with the cerebrospinal fluid. The ependymal cells of the choroid plexus have multiple kinocilium on their apical membranes that beat to move CSF through the ventricles. A sample of CSF can be obtained by lumbar puncture. This reveals intracranial pressure and can indicate disease, including infection of the brain or surrounding meninges.

[0117] Synovial fluid samples are particularly preferred in the context of the present invention for diagnosing joint infections, especially in the case of prosthetic joint infections. Synovial fluid, also known as synovial membrane, is a viscous, non-Newtonian fluid found in the cavities of synovial joints. Its primary role is to reduce friction between the articular cartilage of synovial joints during movement. Synovial fluid is a minor component of the extracellular fluid component. The inner lining of synovial joints, called the synovial membrane, secretes synovial fluid into the joint cavity. Synovial fluid is an ultrafiltrate from plasma and contains proteins derived from plasma and proteins produced by cells within the articular tissue. This fluid contains hyaluronic acid secreted by fibroblast-like cells in the synovial membrane, lubricin (proteoglycan 4; PRG4) secreted by surface chondrocytes of the articular cartilage, and interstitial fluid filtered from plasma. This fluid forms a thin layer (approximately 50 μm) on the surface of the cartilage and also seeps into microcavities and irregularities in the articular cartilage surface, filling all empty spaces. Fluid within articular cartilage effectively serves as a synovial reservoir. During movement, synovial fluid retained within the cartilage is mechanically expressed to maintain a layer of fluid on the cartilage surface (so-called exudative lubrication). Synovial functions include, among other things, friction reduction, shock absorption, and nutrient and waste transport in the joint. Synovial tissue is sterile and consists of vascularized connective tissue lacking a basement membrane. Synovial fluid can be collected with a syringe in a procedure called arthrocentesis, also known as joint aspiration.

[0118] Synovial fluid may be classified as normal, non-inflammatory, inflammatory, septic, and hemorrhagic, where parameters evaluated may include viscosity, clarity, color, and white blood cell count. Such parameters may be evaluated in addition to D-lactate levels in the context of certain embodiments of the present invention.

[0119] The phrase "determining the level of D-lactate" refers to the quantitative measurement or detection of D-lactate. In the context of electrochemical measurements, the level of D-lactate can be determined using various measured parameters, such as voltage or current, that correspond to a specific concentration of D-lactate. In spectrophotometric measurements, the absorbance of chemicals can be determined to determine the amount of each substance.

[0120] Lactate is a salt and ester of lactic acid. Lactic acid exists in two enantiomeric forms, which is why two corresponding forms of its anion, lactate, also exist, usually referred to as the D-form and the L-form according to their orientation in the Fischer projection. Lactic acid is a strong carboxylic acid that dissociates strongly under physiological conditions. The anion has the structural formula CH3-CHOH-COO- and is called lactate. Lactate formed in the human body exists only in the L(+) form, which rotates clockwise.

[0121] Lactic acid esters (CH3-CHOH-COOR) are also called lactates. Ethyl lactate (lactic acid ethyl ester) is the most important representative of these esters and is used, among other things, as a solvent. Another representative is butyl lactate (lactic acid butyl ester).

[0122] The most common lactate found in the human body is sodium lactate. It is produced primarily in skeletal muscle. When glucose or glycogen is broken down into pyruvate during glycolysis, the coenzyme NAD+ is reduced to NADH / H+. For glycolysis to occur, it must exist in its oxidized form as NAD+. It can only act as an electron acceptor in the oxidation of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate by glyceraldehyde-3-phosphate dehydrogenase. In muscle fibers poor in mitochondria, not all of the NADH / H+ can be oxidized as quickly as load increases, so the organism supports itself by reducing pyruvate to lactate. NADH / H+ is reoxidized to NAD+ during this process. The reduction of glucose to lactate is also known as homofermentative lactic acid fermentation. In medicine, L-lactate is used as a marker of ischemia because it is formed in tissues when oxygen is lacking.

[0123] Microorganisms also produce lactate during lactic acid fermentation and, in contrast to humans, are also able to form the D-isomer via D-lactate dehydrogenase.

[0124] Lactate dehydrogenase (LDH or LD) is an enzyme found in nearly all living cells. LDH converts NAD+ to NADH and vice versa, and therefore catalyzes the conversion of lactate to pyruvate and vice versa. Dehydrogenases are enzymes that transfer hydrides from one molecule to another.

[0125] D-lactate dehydrogenase (D-lactate dehydrogenase, D-LDH, D-specific lactate dehydrogenase, D-(-)-lactate dehydrogenase (NAD+), D-lactate dehydrogenase, D-lactate dehydrogenase) has the systematic name (R)-lactate:NAD + It is an enzyme with oxidoreductase activity. This enzyme catalyzes the following chemical reaction: [ka] D-LDH is a preferred D-lactate binding molecule of the present invention. D-LDH is a preferred D-lactate binding molecule of the present invention. A preferred D-LDH is Staphylococcus epidermidis D-LDH.

[0126] In the context of the present invention, a D-lactate binding molecule is any type of molecule that specifically binds to D-lactate but does not bind to L-lactate or other molecules structurally related to D-lactate. In a preferred embodiment, the D-lactate binding molecule is an enzyme that binds to D-lactate to catalyze a reaction involving D-lactate as a substrate. Most preferably, the D-lactate binding molecule is D-LDH.

[0127] Additional D-lactate binding molecules for use in the context of the present invention include, but are not limited to, D-LDH (e.g., D-LDH of microbial origin, such as D-LDH from Staphylococcus epidermidis); D-lactate oxidase (e.g., D-lactate oxidase of microbial origin, such as D-lactate oxidase from Gluconobacter or Zymomonas mobilis).

[0128] In the context of the methods of the present invention, the determined level of D-lactate can indicate the presence of an infection, where the determined level can be compared to an appropriate control (e.g., a control sample or multiple samples from a control group (e.g., healthy individuals)) or to a reference value (e.g., a threshold or cut-off value), where a concentration higher than the control sample or equal to or greater than the reference value can indicate an infection or provide prognostic value for the progression of the infection.

[0129] When determining PJI, the control group can be patients with artificial joints who do not suffer from PJI. Based on a comparison of the determined levels of D-lactate in samples from individuals suffering from each infection of interest with the levels determined for an appropriate control group, appropriate reference values ​​can be derived, for example, a cutoff or threshold level of D-lactate above which indicates the presence of each infection.

[0130] A control value / control sample or standard can be used in the context of the present invention to provide a sample containing D-lactate or represent a control amount thereof, as already obtained from a previous analytical test. It is possible to use a control value generated by testing a cohort or other large number of subjects suffering from any infectious disease or control group. Suitable statistical tools for the analysis and comparison of such data sets are known to those skilled in the art. Control samples for positive controls (such as diseased patients) or negative controls (from healthy subjects) can be used as reference values ​​in either simultaneous or non-simultaneous comparisons.

[0131] As used herein, an "electrochemical sensing system," which may also be referred to as a "biosensor," refers to an analytical device used for the detection of a substance / analyte (in this case, D-lactate) that combines a biological component with an electrochemical detector. Sensors are biologically derived materials or biomimetic components that interact with, bind to, or recognize the chemical analyte of interest, and include sensitive biological elements, such as tissues, microorganisms, organelles, molecules, cellular receptors, enzymes, antibodies, nucleic acids, etc. Biological sensitive elements can also be produced by bioengineering.

[0132] The biosensor further comprises a transducer or detector element that converts the signal resulting from the interaction of the analyte with the biological element into an electrochemical signal, based on which the level of the analyte in the sample can be readily measured and quantified.

[0133] The electrochemical system may include or be connected to a biosensor reader with associated electronics or a signal processor for interfacing with the transformer, such a reader preferably being responsible for displaying the results in a user-friendly manner.

[0134] The biosensor of the present invention can comprise a biorecognition moiety, a biotransducer component, and preferably an electronic system including one or more of a signal amplifier, a processor, and a display. The recognition component, often referred to as a bioreceptor, interacts with the analyte of interest using a biomolecule from an organism or a receptor modeled after a biological system. This interaction is measured by the biotransducer, which outputs a measurable signal proportional to the presence of the target analyte in the sample. A general goal of biosensor design is to enable rapid and convenient testing at the point-of-care (POC) where the sample is procured.

[0135] Bioreceptors are designed to interact with a specific analyte of interest to produce a measurable effect via a transducer. High selectivity for the analyte in a matrix of other chemical or biological components is a key requirement for a bioreceptor. While the type of biomolecule used can vary widely, biosensors can be classified according to general types of bioreceptor interactions, including antibody / antigen, enzyme / ligand, nucleic acid / DNA, cellular structure / cell, or biomimetic materials. In the context of the present invention, the bioreceptor is preferably a D-LDH-binding molecule, such as D-LDH. Thus, the biosensor / electrochemical sensing system of the present invention preferably includes an enzyme / ligand interaction.

[0136] The specific binding capacity and catalytic activity of enzymes make them advantageous general bioreceptors for several reasons, including their compatibility with several different transfection methods for detecting analytes. Notably, because enzymes are not consumed in the reaction, biosensors can easily be used continuously. The catalytic activity of enzymes also allows for a lower limit of detection compared to general binding techniques.

[0137] Preferably, in the context of a biosensor / electrochemical sensing system, the biological component, here a D-lactate-binding molecule, e.g., D-LDH, is attached to the surface of the sensor, which may be, for example, metal, polymer, or glass. The simplest method is to functionalize the surface so that it is coated with the biological component. In the case of silicon chips / silica glass, this can be done with polylysine, aminosilane, epoxysilane, or nitrocellulose. The bound biological agent can then be immobilized, for example, by layer-by-layer deposition of an alternatively charged polymer coating. Alternatively, three-dimensional lattices (hydrogels / xerogels) can be used to chemically or physically entrap them (here, chemically entrapped means that the biological components are held in place by strong bonds, while physically they are held in place so that they cannot pass through the pores of the gel matrix). The most commonly used hydrogels are sol-gels, glassy silica produced by polymerization of silicate monomers (added as tetraalkyl orthosilicates such as TMOS or TEOS) in the presence of biological components (along with other stabilizing polymers such as PEG) in the case of physical entrapment. Another group of hydrogels that cure under conditions suitable for cells or proteins are acrylate hydrogels, which polymerize upon radical initiation. One type of radical initiator is peroxide radicals, typically generated by combining persulfate with TEMED (polyacrylamide gels are also commonly used for protein electrophoresis). Alternatively, light can be used in combination with a photoinitiator such as DMPA (2,2-dimethoxy-2-phenylacetophenone).

[0138] Electrochemical biosensors are typically based on enzymatic catalysis of reactions that produce or consume electrons (such enzymes are properly called redox enzymes). The sensor substrate typically contains three electrodes: a reference electrode, a working / detecting electrode, and a counter electrode. The target analyte participates in a reaction that occurs on the active electrode surface, which can either cause electron transfer across the double layer (generating a current) or contribute to the double layer potential (generating a voltage). Thus, it is possible to measure the current at a fixed potential (where the electron flux is proportional to the analyte concentration) or the potential can be measured at zero current (which gives a logarithmic response). Note that the potential of the working / detecting / active electrode is space charge sensitive, and this is often used.

[0139] Potentiometric biosensors (potential generated at zero current) provide a logarithmic response with a high dynamic range. Such biosensors are often fabricated by screen-printing an electrode pattern onto a plastic substrate coated with a conducting polymer, followed by attachment of an enzyme / biosensor. They have only two electrodes and are extremely sensitive and robust. They enable the detection of analytes without rigorous sample preparation, at levels previously achievable only by HPLC and LC / MS.

[0140] All biosensors typically involve minimal sample preparation, as the biological sensing components are highly selective for the analyte of interest. Signals are generated by electrochemical and physical changes in the conducting polymer layer due to changes occurring at the sensor's surface. Such changes can be attributed to ionic strength, pH, hydration, and redox reactions, the latter resulting from enzyme labeling turning over substrate. Field-effect transistors, whose gate region is modified with an enzyme / biosensor, can also detect very low concentrations of various analytes, as binding of the analyte to the gate region of the FET causes a change in the drain-source current.

[0141] The electrochemical biosensor of the present invention is used for the in vitro measurement of D-lactate in a sample. Biosensor measurements can be performed in test tubes, culture dishes, microtiter plates, or elsewhere outside the body. The sensor uses a bioreceptor and a transducer, as outlined above. The present invention can preferably be used for point-of-care testing (POCT), i.e., at the location where testing is needed. Therefore, the biosensor of the present invention is preferably a wearable or portable, preferably handheld, biosensor. Eliminating laboratory testing can save time and money. The POCT biosensor can be sent directly to the location, allowing for quick and easy testing.

[0142] The electrochemical sensing methods of the present invention preferably include techniques in analytical chemistry that study analytes by measuring the potential (volts) and / or current (amperes) in an electrochemical cell containing the analyte. These methods can be divided into several categories depending on which aspect of the cell is controlled and which aspect is measured. The three main categories are amperometric methods, including potentiometry (where the difference in electrode potentials is measured), coulometry (where the cell's current is measured over time), and voltammetry (where the cell's current is measured while actively changing the cell's potential).

[0143] Potentiometry passively measures the potential of a solution between two electrodes, with little effect on the solution in the process. One electrode, called the reference electrode, has a constant potential, while the other electrode, the sensing or working electrode, changes its potential depending on the sample's composition. Therefore, the potential difference between the two electrodes provides an estimate of the sample's composition. In fact, potentiometry is a nondestructive measurement; the solution potential is measured assuming the electrode is in equilibrium with the solution. Potentiometry typically uses a sensing electrode selectively sensitive to the ion of interest, such as fluoride in a fluoride-selective electrode, so the potential depends only on the activity of this ion. The time it takes the electrode to establish equilibrium with the solution will affect the sensitivity or accuracy of the measurement. In aquatic environments, platinum is often used due to its high electron transfer reaction rate, but electrodes made from several metals can be used to enhance the electron transfer reaction rate. The most common potentiometric electrode is the glass membrane electrode used in pH meters by a significant margin. A variation of potentiometry is chronopotentiometry, which consists of using a constant current and measuring the potential as a function of time.

[0144] Potentiometric sensors are a type of chemical sensor that can be used to determine the analytical concentration of an analyte in a sample. These sensors measure the potential of an electrode in the absence of current. The signal is measured as the potential difference (voltage) between the sensing / working electrode and the reference electrode. The potential of the working electrode necessarily depends on the concentration of the analyte in the sample. A reference electrode is required to provide a defined reference potential.

[0145] Among various potentiometric techniques, field-effect transistor (FET)-based sensing has attracted considerable attention due to its potential for miniaturization, parallel sensing, fast response time, and seamless integration with electronic fabrication processes such as complementary metal-oxide semiconductor (CMOS). A field-effect transistor (FET) is a type of transistor that uses an electric field to control the flow of current.

[0146] The concept of ion-sensitive FETs (ISFETs) was introduced in the early 1970s and derived from metal-oxide-semiconductor FETs (MOSFETs). An ion-sensitive field-effect transistor (ISFET) is a field-effect transistor used to measure ion concentrations in solution; changes in ion concentration (such as H+, see the pH scale) cause a corresponding change in the current flowing through the transistor. Here, the solution is used as the gate electrode. A voltage is generated between the substrate and the oxide surface via an ion sheath. It is a specialized type of MOSFET (metal-oxide-semiconductor field-effect transistor) and shares the same basic structure, but the metal gate is replaced by an ion-sensitive membrane, an electrolyte solution, and a reference electrode. The ISFET was the first biosensor FET (BioFET).

[0147] A field-effect transistor-based biosensor, also known as a biosensor field-effect transistor (Bio-FET or BioFET), field-effect biosensor (FEB), or biosensor MOSFET, is a specific potentiometric sensor. It is a field-effect transistor (based on MOSFET structure) gated by changes in surface potential induced by molecular binding. The binding of charged molecules, such as biomolecules, to the FET gate, which is typically a dielectric material, can alter the charge distribution in the underlying semiconductor material, potentially changing the conductance of the FET channel. A Bio-FET consists of two main compartments: one is the biological recognition element, and the other is the field-effect transistor. The BioFET structure is largely based on the ion-sensitive field-effect transistor (ISFET), a type of metal-oxide-semiconductor field-effect transistor (MOSFET) in which the metal gate is replaced by an ion-sensitive membrane, an electrolyte solution, and a reference electrode.

[0148] Bio-FETs combine transistor elements with a biosensitive layer capable of specifically detecting biologically relevant molecules, such as enzyme substrates, nucleic acids, and proteins. Bio-FET systems consist of a semiconductor field-effect transistor acting as a transducer, separated by an insulator layer (e.g., SiO2) from a biological recognition element (e.g., enzyme, receptor, or probe molecule) that is selective for a target molecule called the analyte. When the analyte binds to the recognition element, the charge distribution at the surface changes with a corresponding change in the electrostatic surface potential of the semiconductor. This change in the semiconductor's surface potential acts like the gate voltage in a conventional MOSFET, changing the amount of current that can flow between the source and drain electrodes. This change in current (or conductance) can be measured, allowing analyte binding to be detected. The exact relationship between current and analyte concentration depends on the operating region of the transistor. The fabrication of a Bio-FET system consists of several steps, for example: 1. finding a suitable substrate to serve as the FET site and forming a FET on the substrate; 2. exposing the active site of the FET from the substrate; 3. providing a sensing membrane layer on the active site of the FET; 4. providing a receptor on the sensing membrane layer to be used for ion detection; 5. removing the semiconducting layer and thinning the dielectric layer; 6. etching the remaining part of the dielectric layer to expose the active site of the FET; 7. removing the photoresist and depositing the sensing membrane layer, followed by forming a photoresist pattern on the sensing membrane; 8. etching the unprotected part of the sensing membrane layer and removing the photoresist. BioFET sensors and their underlying principles are known to those skilled in the art, for example from the publication by Kaisti M (2017) (Biosensors and Bioelectronics Volume 98, 15 December 2017, Pages 437-448).

[0149] Electrochemical sensing systems (biosensors), particularly Bio-FETs, can be used for detection in fields such as medical diagnostics, biological research, environmental protection, and food analysis. Conventional measurements, such as optical and spectroscopic measurements, can also be used to analyze biological molecules. Nevertheless, these conventional methods are relatively time-consuming and expensive, involve multi-step processes, and are not compatible with real-time monitoring. In contrast, biosensors such as Bio-FETs are low-weight, low-cost for mass production, compact, and compatible with commercially available planar processes for large-scale circuits. They can be easily integrated into digital microfluidic devices for lab-on-a-chip applications. For example, microfluidic devices use an all-in-one chip to control sample droplet transport while enabling biomolecule detection, signal processing, and data transmission. Furthermore, they can be used in handheld point-of-care devices. The method of the present invention does not require any labeling step and simply utilizes the specific molecular properties of the sensor, preferably the sensor surface, to provide selectivity.

[0150] Coulometry is another electrochemical sensing technique that can be used in the context of the present systems. It uses an applied current or potential to completely convert an analyte from one oxidation state to another. The total current passed is then measured, either directly or indirectly, to determine the number of electrons passed. Knowing the number of electrons passed can indicate the concentration of the analyte, or, if the concentration is known, the number of electrons transferred in a redox reaction. Common forms of coulometry include bulk electrolysis, also known as controlled-potential or controlled-potential coulometry, as well as various coulometric titrations.

[0151] Amperometric sensors are further preferred electrochemical systems of the present invention. Amperometry is a term that refers to the whole range of electrochemical techniques in which current is measured as a function of an independent variable, typically time or electrode potential. Chronoamperometry is a technique in which current is measured at a constant potential at different times after polarization begins. Chronoamperometry is typically performed in unstirred solutions and at fixed electrodes, i.e., under experimental conditions that avoid convection as a mass transfer to the electrode. Voltammetry, on the other hand, is a subclass of amperometry, in which current is measured by varying the potential applied to the electrode. Different voltammetric techniques are defined according to the waveform that describes how the potential changes as a function of time.

[0152] In single-potential amperometry, any analyte that can be oxidized or reduced is a candidate for amperometric detection. The simplest form of amperometric detection is single-potential, or direct current (DC), amperometry. A voltage (potential) is applied between two electrodes placed in the column effluent. The measured current changes as the electroactive analyte is oxidized at the anode or reduced at the cathode. Single-potential amperometry has been used to detect weak acid anions, such as cyanide and sulfide, that are problematic for conductometric methods. Another, perhaps more important, advantage of amperometry over other detection methods is specificity. The applied potential can be adjusted to maximize the response to the analyte of interest while minimizing the response to interfering analytes.

[0153] An extension of single-potential amperometry is pulsed amperometry, which is most commonly used for analytes that tend to foul the electrode. Analytes that foul the electrode reduce the signal with each analysis and require electrode cleaning. In pulsed amperometric detection (PAD), a working potential is applied for a short period (usually a few hundred milliseconds), followed by a higher or lower potential used to clean the electrode. The current is measured only while the working potential is applied, and sequential amperometric measurements are then processed by the detector to generate a smooth output. While PAD is most frequently used for the detection of carbohydrates after anion-exchange separation, further development of related techniques shows promise for amines, reduced sulfur species, and other electroactive compounds.

[0154] In a further embodiment of the present invention, the electrochemical sensing system is a voltammetry system. Voltammetry involves applying a constant and / or varying potential to the surface of an electrode and measuring the resulting current using a three-electrode system. This method can reveal the reduction potential of an analyte and its electrochemical reactivity. This method is practically nondestructive because only a very small amount of analyte is consumed on the two-dimensional surface of the working / detecting and auxiliary electrodes. In practice, the analyte solution is typically discarded due to the difficulty of separating the analyte from the bulk electrolyte and the experiment requiring small amounts of analyte. A typical experiment may involve 1 to 10 mL of solution with an analyte concentration between 1 and 10 mmol / L. Chemically modified electrodes are used for the analysis of organic and inorganic samples. Polarography is a subclass of voltammetry that uses a dropping mercury electrode as the working electrode.

[0155] The electrochemical sensing systems of the present invention may require calibration to provide the concentration of D-lactate as a measurement output. For example, the system may be calibrated either "on-strip," where each test run is calibrated against the response generated by a standard sample present in the capillary sample chamber, or, for example, at the factory prior to shipment. The standard sample used for calibration contains a defined, known concentration of the analyte, here D-lactate. Furthermore, in embodiments, the electrochemical sensing system may be a calibration-free system. Such systems are known in the art, for example, systems that use a "dual-frequency" approach to achieve calibration-free operation of electrochemical biosensors that generate output by using square-wave voltammetry to monitor binding-induced changes in electron transfer kinetics.

[0156] The electrode configurations required for various electrochemical sensing systems that can be used in the context of the present invention have been described in the art and are known to those skilled in the art, including preferred electrode materials and surface modifications, as well as possible methods for immobilizing molecules on the electrode surface (see, for example, Comprehensive Nanoscience and Nanotechnology (Second Edition), Volume 3, 2019, in particular Agnieszka A. Zuber et al., 3.06 - Biosensing, Pages 105-126; Handbook of Electrochemistry, 2007, in particular Grant A. Edwards et al., 8 - Chemically Modified Electrodes, pages 295-327; Kenneth L. Brown, Electrochemical Preparation and Characterization of Chemically Modified Electrodes, DOI: 10.5772 / intechopen.81752). The choice of the respective electrode material, electrode modification and / or possibility of immobilizing or attaching molecules onto the electrode depends on the respective application and the expected concentration range to be detected.

[0157] In embodiments, the electrochemical sensing system comprises a test strip or chip for electrochemical detection of D-lactate. The test strip may include or consist of a paper-based sensor for use in a point-of-care device, such as a handheld reader. The test strip may be combined with electrochemical detection using small and portable electronic devices. Furthermore, the test strip or chip may be or include a flexible material, such as paper, plastic, or textile, as a support for a biosensing platform, which may be used in the context of a microfluidic device, a lab-on-a-chip (LOC) biosensing device, or a POC device.

[0158] The electrochemical sensing system of the present invention can be configured for parallel detection of D-lactate levels in multiple samples by providing several electrochemical cells that allow for multiplexing.

[0159] (drawing) The present invention is further illustrated by the following drawings, which are not intended to limit the scope of the invention, but rather represent preferred embodiments of aspects of the invention provided for greater illustration of the invention described herein. [Brief explanation of the drawings]

[0160] [Figure 1A] Distribution of leukocytes in synovial fluid (left panel) and corresponding receiver operating characteristic (ROC) curve (right panel). AF: aseptic failure, PJI: periprosthetic joint infection, AUC: area under the curve. [Figure 1B] Distribution of the percentage of granulocytes in synovial fluid (left panel) and the corresponding receiver operating characteristic (ROC) curve (right panel). AF: aseptic failure, PJI: periprosthetic joint infection, AUC: area under the curve. [Figure 1C] Distribution of D-lactate in synovial fluid (left panel) and corresponding receiver operating characteristic (ROC) curve (right panel). AF: aseptic failure, PJI: periprosthetic joint infection, AUC: area under the curve. [Figure 2] Synovial fluid D-lactate concentrations stratified by pathogen. [Figure 3] ROC curves of synovial fluid biomarkers for PJI. The AUCs for D-lactate, white blood cell count, and granulocyte percentage are 0.903, 0.910, and 0.861, respectively. [Figure 4A] Distribution of D-lactate in patients with aseptic disorders and PJI. The 12 cases with underlying inflammatory conditions and elevated white blood cell counts or granulocyte percentages above threshold are shown as dark grey dots. [Figure 4B] Distribution of white blood cell counts in patients with aseptic disorders and PJI. The 12 cases with underlying inflammatory conditions and elevated white blood cell counts or granulocyte percentages above threshold are shown as dark grey dots. [Figure 4C]Distribution of granulocyte percentages in patients with aseptic disorders and PJI. The 12 cases with underlying inflammatory conditions and elevated white blood cell counts or granulocyte percentages above threshold are shown as dark grey dots. [Figure 5] Results of synovial fluid D-lactate test and white blood cell count in early postoperative PJI (A) and delayed or late PJI (B). The difference in early PJI was significant (p=0.027), but there was no significant difference between delayed and late PJI (p=0.572). [Figure 6] Correlation of synovial fluid red blood cell and D-lactate concentrations in patients with aseptic injury and PJI. Note: ρ = Pearson correlation. [Figure 7] Electrochemical D-lactate measurement using potentiometry. Different concentrations of D-lactate (monolithium salt) as standard calibrator and the corresponding voltage. The average values ​​are shown and the error bars represent the standard deviation. [Figure 8] Electrochemical D-lactate measurement using amperometry. Different concentrations of D-lactate (sodium D-lactate) as a standard calibrator in phosphate buffer (pH 6.5) and the corresponding current. The average values ​​are shown and the error bars represent the standard deviation. [Figure 9] Electrochemical D-lactate measurement using amperometry. Different concentrations of D-lactate (sodium D-lactate) as a standard calibrator in phosphate buffer (pH 8.5) and the corresponding current. The average values ​​are shown and the error bars represent the standard deviation. [Example]

[0161] The present invention is further illustrated by the following examples and comparative examples, which are not intended to limit the scope of the invention but rather represent preferred embodiments of aspects of the invention provided for greater illustration of the invention described herein.

[0162] Example 1: Synovial fluid D-lactate as a pathogen-specific biomarker for accurate and rapid detection of periprosthetic joint infection

[0163] Materials and Methods for Example 1 Study Design and Population. Consecutive patients aged 18 years or older who underwent diagnostic joint aspiration of hip, knee, and shoulder prostheses between July 2016 and June 2018 were prospectively included. Painful joints were aspirated as part of a routine diagnostic procedure before capsule dissection in the emergency room, outpatient clinic, or operating room. Patients in whom the aspirated synovial fluid was diluted with intravenous fluid were excluded. Institutional review board approval was obtained, and the study was registered with the public clinical trial registry www.clinicaltrials.gov (NCT02530229). Patients provided written informed consent for inclusion in the study. D-lactate results were not shared with treating physicians and did not influence treatment decisions.

[0164] Definition. PJI was diagnosed according to the operational criteria of the European Bone and Joint Infection Society (EBJIS), as performed in several studies (Non-Patent Documents 5, 7, 15-20). Therefore, PJI was diagnosed if one or more of the following criteria were met: (i) the presence of a sinus tract or macroscopic suppuration; (ii) positive histopathological inflammation of the periprosthetic tissue, defined as 23 or more granulocytes per 10 high-power fields (i.e., type II or III according to Krenn et al. (Non-Patent Document 21)); (iii) 2 × 10 3 (iv) positive synovial fluid, periprosthetic tissue, or sonicated fluid cultures. Sonicated cultures were considered positive if ≥50 colony-forming units (CFU) / mL were detected, except for Staphylococcus aureus, streptococci, and gram-negative bacilli, for which any growth (i.e., ≥1 CFU / mL) was considered positive (Non-Patent Document 22). Of note, synovial fluid leukocyte counts were not considered diagnostic criteria within 6 weeks of surgery for inflammatory joint disease and in cases of periprosthetic fractures or dislocations. In these situations, leukocyte counts may also be elevated in the absence of infection (Non-Patent Document 19).

[0165] Specimen collection. Joint aspiration was performed by orthopedic surgeons at the time of revision according to standardized aseptic technique in the emergency room, outpatient department, and / or during surgery. No patients received antibiotic treatment before joint aspiration.

[0166] Conventional microbiological testing. Each synovial fluid sample was inoculated in 0.1 ml aliquots onto tryptic soy agar containing 5% sheep blood, chocolate agar, and thioglycollate broth. Additionally, each sample was inoculated into blood culture pediatric vials, VersaTREK (TREK Diagnostic Systems, Cleveland, OH, USA), at the first center, and BacTec PedsPlus / F (Beckton Dickinson and Co., Shannon, County Clare, Ireland), at the second center. All culture media were incubated at 35°C for 14 days. Identification and susceptibility testing of isolated microorganisms were performed using an automated bacteriological analyzer, WalkAway 96 Plus (Beckman Coulter, Brea, CA, USA), at the first center, and an automated system, VITEK 2 (bioMérieux, Marcy-l'Etoile, France), at the second center.

[0167] Measurement of synovial fluid leukocyte count and differential leukocyte count. To measure the leukocyte count and granulocyte percentage, 1 ml of synovial fluid was transferred to a vial containing ethylenediaminetetraacetic acid (EDTA). The clotted specimen was treated with 10 μl of hyaluronidase (Sigma-Aldrich Chemie, Taufkirchen, Germany) at room temperature for 10 minutes. Analysis was performed by flow cytometry using an automated hematology analyzer (XE-2100, Sysmex, Norderstedt, Germany).

[0168] Measurement of D-lactate in synovial fluid. To measure D-lactate concentrations using a spectrophotometrically based commercially available kit (D-Lactam diagnostic kit, Sivital, Vitebsk, Republic of Belarus), 0.5–1 ml volumes of samples were placed in sterile plastic native vials. A reaction mixture containing 0.025 ml of pretreated sample, 0.08 ml of substrate mix, and 0.045 ml of enzyme mix, and a blank containing only the sample and substrate mix, were analyzed for each patient. A calibration curve using a solution of D-lactate (monolithium salt) in water was prepared in each batch. The mixtures were incubated at 37°C for 30 minutes, and the absorbance at 570 nm was determined using a Microplate Absorbance Reader (DYNEX Technologies MRX, Chantilly, VA, USA). The optical density of each sample was used as a measure of D-lactate concentration.

[0169] Statistical Analysis. The significance level for all hypothesis testing procedures was predefined as p<0.05. Quantitative data were presented as median (range) or mean and standard deviation (SD), as appropriate. The Mann-Whitney test and Spearman correlation were applied to analyze quantitative variables. The optimal cutoff value was calculated by maximizing sensitivity and specificity. Youden's J statistic was used to determine the optimal D-lactate cutoff value on the receiver operating characteristic (ROC) curve. The ROC curve was calculated to detect the parameter with the highest diagnostic potential, and the area under the ROC curve was estimated. All statistical analyses were performed using MedCalc 16.4.3 (MedCalc Software bvba, Ostend, Belgium). For graphics, the software Prism (version 7.03; GraphPad, La Jolla, CA, USA) was used.

[0170] Results of Example 1 Patient demographics and infection characteristics. Of the 224 patients included, 87 were diagnosed with PJI and 137 patients with aseptic prosthetic joint failure were assigned to the control group. Demographic data and affected joints stratified into aseptic and infected groups are shown in Table 1. The hip joint was more commonly infected than the knee joint.

[0171] Synovial fluid microbiology. Of the 87 patients with PJI, synovial fluid cultures grew the causative organism in 61 (70%) (Table 2). Of the 137 patients with aseptic disorders, 9 (6.6%) patients with prosthetic joints had positive synovial fluid cultures and were considered contaminated with non-significant growth.

[0172] Synovial fluid leukocyte count and differential count. The absolute synovial fluid leukocyte count had a sensitivity of 87.5% and a specificity of 95.7%. The percentage of granulocytes had a sensitivity of 80.4% and a specificity of 99.2% (Table 3).

[0173] Synovial fluid D-lactate. The optimal D-lactate cutoff was 1.2 mmol / L. Significantly higher mean (±SD) concentrations of D-lactate were observed in synovial fluid from patients with PJI compared with patients with aseptic disorders (2.33 ± 0.63 mmol / L vs. 0.77 ± 0.56 mmol / L, p < 0.001, Figure 1). The sensitivity of D-lactate testing was 97.7%, and the specificity was 83.9% (Table 3).

[0174] In patients with aseptic disorders, D-lactate concentrations were elevated above the cutoff value in 20 patients. Eight of the false-positive synovial fluid samples from aseptic disorders had normal white blood cell counts (range 127 / μl to 1237 / μl), demonstrating contamination with skin flora pathogens.

[0175] In two patients with PJI, D-lactate concentrations were falsely negative. In one patient with PJI, the diagnosis was based on a positive synovial fluid culture (Staphylococcus haemolyticus) in combination with an elevated synovial leukocyte count, and in the second patient with PJI, the presence of a sinus tract confirmed the infection.

[0176] Synovial fluid D-lactate concentrations by pathogen. Highly virulent bacteria (Staphylococcus aureus and Streptococcus species) had significantly higher mean D-lactate concentrations than typical low-virulence pathogens, coagulase-negative staphylococci (p = 0.019 and p = 0.004, respectively; see Figure 2). When comparing D-lactate concentrations in culture-negative infections with those caused by low-virulence microorganisms (i.e., coagulase-negative staphylococci), no significant differences in D-lactate concentrations were observed (p = 0.531). In one patient with PJI caused by Candida parapsilosis, the D-lactate concentration exceeded the cutoff value (2.7 mmol / L).

[0177] Consideration of Example 1 Previous reports have demonstrated that synovial fluid D-lactate is highly sensitive and specific for diagnosing septic arthritis (Non-Patent Documents 11, 12), but this biomarker has not yet been investigated in PJI. In our study, synovial fluid D-lactate showed higher sensitivity than synovial fluid leukocyte count and granulocyte percentage, but its specificity for diagnosing PJI was lower. Gratacos et al. reported high diagnostic performance (AUC 0.90), high sensitivity (86%), specificity (96%), and high negative predictive value (97%) of synovial fluid D-lactate using a cutoff value of 0.05 mmol / L (Non-Patent Document 11). Kortekangas et al. showed that the median D-lactate concentration was significantly higher in culture-positive synovial fluid samples compared with culture-negative synovial fluid samples from patients with extra-articular infection (p = 0.006) (Non-Patent Document 12).

[0178] In this study, the optimal synovial fluid D-lactate cutoff value for the diagnosis of PJI was 1.2 mmol / L. D-lactate was statistically higher in highly virulent bacteria (e.g., Staphylococcus aureus and Streptococcus species) compared with less virulent pathogens (e.g., coagulase-negative staphylococci), with no difference observed in the latter PJI group and culture-negative infections. D-lactate concentrations likely reflect the virulence of the bacterial species and its microbial load, explaining the observed differences.

[0179] Interestingly, one patient with PJI caused by Candida parapsilosis showed a significantly increased D-lactate concentration (2.7 mmol / L). This unusual finding could be explained by concurrent infection with an additional unidentified bacterium. Alternatively, local oxygen limitation could lead to alcoholic fermentation in yeast, during which glycerol, pyruvate, and D-lactate are produced as the major fermentation products (Non-Patent Document 23). As reported in Saccharomyces cerevisiae, growing fungal pathogens in high-glucose media may increase D-lactate production and reduce overall glucose utilization efficiency (Non-Patent Document 24).

[0180] Furthermore, it is important to recognize rare conditions that cause D-lactate acidosis and increase D-lactate in blood and body fluids, namely short bowel syndrome, especially in the context of a high-carbohydrate diet in children. The concurrent occurrence of severe, uncontrolled diabetes with insulin deficiency can also lead to elevated D-lactate levels in plasma and urine (Non-Patent Document 25). Further research is needed to explore underlying conditions that may affect D-lactate concentrations, which may explain the limited specificity of the test.

[0181] Synovial fluid D-lactate showed good diagnostic performance for diagnosing PJI, comparable to synovial fluid white blood cell count or differential white blood cell count. The advantages of the D-lactate test are its small synovial fluid volume requirement (50 μl), short turnaround time (45 minutes), and low cost. In particular, the high sensitivity and rapid availability of results make the test particularly useful as a screening tool for PJI. To increase specificity, a confirmatory diagnostic test in synovial fluid may be included in the diagnostic algorithm for PJI.

[0182] Example 2: Performance of D-lactate in synovial fluid for the diagnosis of periprosthetic joint infection: a prospective observational study Materials, Patients and Methods for Example 2 Study design and population. This prospective diagnostic cohort study included consecutive patients aged 18 years or older who underwent evaluation of a painful prosthetic hip, knee, or shoulder joint between May 2016 and March 2017 and underwent diagnostic joint aspiration before revision prosthetic joint replacement to evaluate for infection. Only one (first-obtained) synovial fluid sample per patient was considered.

[0183] Patients with diluted synovial fluid after joint instillation, insufficient synovial fluid volume (<3 mL), or synovial fluid analysis performed more than 48 hours after aspiration were excluded. A standardized case report form was used to collect patient history, demographic, clinical, radiological, microbiological, histopathological, and laboratory data. All patients were evaluated by a multidisciplinary team consisting of an orthopedic surgeon, an infectious disease specialist, and an internal medicine specialist. Synovial fluid D-lactate test results were not communicated to the treating orthopedic surgeon. This study was conducted in accordance with the Declaration of Helsinki.

[0184] Diagnosis of Periprosthetic Joint Infection. PJI was defined according to the European Society for Bone and Joint Infection (EBJIS) operational criteria (Non-Patent Document 44) and summarized in Table 4. Acute infection was diagnosed if the infection occurred within 4 weeks after surgery or if the patient reported new-onset symptoms that persisted for 4 weeks or less. Chronic infection was defined as an infection that occurred 4 weeks or more after the final surgery and persisted for 4 weeks or more. Furthermore, based on the interval between the last revision or initial implantation and the time of aspiration, all infections were classified as early (i.e., less than 3 months) and late or late (i.e., longer than 3 months) infections (Non-Patent Document 45).

[0185] Collection and examination of synovial fluid, periprosthetic tissue, and implants. Synovial fluid was aspirated under sterile conditions during outpatient preoperative or revision surgery before capsule opening. 1 ml of synovial fluid was inoculated into a pediatric blood culture bottle (BacTec PedsPlus / F, Beckton Dickinson and Co.), 1 ml was transferred to native vials for aerobic and anaerobic culture (0.1 ml each), and the remaining fluid was inoculated into thioglycollate broth for concentration. The pediatric blood culture bottles were incubated at 36 ± 1°C for 14 days or until growth was detected. Aerobic cultures were incubated at 37°C and examined daily for 7 days, and anaerobic cultures were incubated for 14 days. Microbial colonies were identified by standard microbiological methods using the automated VITEK2 system (bioMérieux, Marcy-l'Etoile, France). A 1 ml aliquot was sent to a pathologist for examination of the synovial fluid using polarized light microscopy for the detection of urate and pyrophosphate crystals.

[0186] In addition, if revision surgery was performed, three to five periprosthetic tissue samples were collected intraoperatively from the implant-bone or cement-bone interface for microbiological and histopathological analysis. Periprosthetic tissue cultures were considered positive if one or more samples from synovial fluid, periprosthetic tissue, or sonication grew highly pathogenic microorganisms (Staphylococcus aureus, Enterobacteriaceae, Streptococcus species, Candida species) or two or more samples grew moderately or lowly pathogenic microorganisms (coagulase-negative staphylococci, enterococci, Cutibacterium species [formerly known as Propionibacterium], and other bacteria of the skin microbiome).

[0187] The retrieved prosthetic joint components were sent for sonication as previously described (Non-Patent Document 46). Sonication was considered positive if the sonicated fluid grew ≥1 CFU / ml of highly pathogenic organisms or ≥50 CFU / ml of low pathogenic organisms (Non-Patent Document 47).

[0188] Determination of leukocyte count and granulocyte percentage in synovial fluid. One milliliter of synovial fluid was transferred to a vial containing ethylenediaminetetraacetic acid (EDTA). Leukocyte count was determined by flow cytometry using an automated hematology analyzer (XE-2100, Sysmex, Norderstedt, Germany). Clotted specimens were treated with 10 μl of hyaluronidase (Sigma-Aldrich Chemie, Taufkirchen, Germany) for 10 minutes at room temperature.

[0189] Determination of D-lactate in synovial fluid. D-lactate was determined spectrophotometrically from the optical density of the prepared samples. A 1 ml aliquot was transferred to a native vial for D-lactate determination using a commercially available kit (D-lactam Kit; VL-Diagnostics, Leipzig, Germany). Aliquots for D-lactate determination were stored at 4°C ± 1°C and analyzed within 48 hours after withdrawal. The test was performed according to the manufacturer's instructions. The determination was based on spectrophotometry using a standard microplate absorbance reader at 570 nm, requiring 50 μl of synovial fluid. In the analysis, D-lactate dehydrogenase (D-LDH) converts nicotinamide adenine dinucleotide (NAD) to nicotinamide adenine dinucleotide (NAD). + It catalyzes the oxidation of D-lactate to pyruvate with the concomitant reduction of D-lactate to NADH, which reacts with a fluorescent substrate to color the mixture (Non-Patent Document 48).

[0190] The D-lactam assay included a lithium D-lactate standard for preparation of a calibration curve, which was processed for each batch. The reaction mixture contained 0.025 ml of synovial fluid sample, 0.08 ml of substrate mix, and 0.045 ml of enzyme mix. The turbidity control mixture contained 0.025 ml of synovial fluid sample, 0.08 ml of substrate mix, and 0.045 ml of purified water. The reagents were applied to a flat-bottom 96-well plate, incubated at 37°C for 30 minutes, and then read at 570 nm using a Microplate Absorbance Reader (DYNEX Technologies MRX, Chantilly, VA, USA).

[0191] Statistical analysis. Youden's J statistic was used to determine the D-lactate cutoff point on the ROC curve. The area under the ROC curve (AUC) was used to evaluate the diagnostic performance of the D-lactate test, white blood cell count, and granulocyte percentage. A two-tailed, independent-samples Student's t-test was applied to assess statistical significance in the mean D-lactate concentrations between groups. Sample size calculations were based on the assumption that the sensitivity of D-lactate was 90% compared with 80% for conventional diagnostic tests, including white blood cell count, periprosthetic histopathology, and culture, i.e., a 10% (power 80%) difference. The DeLong test of the two correlation ROC curves was used to determine whether the difference between the AUCs was statistically significant. A significance level of 0.05 was selected for all statistical tests performed. The 95% confidence intervals (CIs) for the AUC were estimated using the DeLong method, and the 95% CIs for the other performance measures were estimated using bootstrap resampling with 10,000 iterations (Table 6). Two independent median, -test, and Fisher's exact test were used to estimate the p-values ​​in Table 5. Bootstrap resampling with 10,000 iterations was performed to estimate the p-values ​​between the sensitivities in Figure 3. The correlation between red blood cell and D-lactate concentrations was estimated using the Pearson coefficient (ρ). IBM SPSS 22.0 (Statistical package for Social Sciences Corporation, Chicago, IL, USA) was used for all statistical analyses. ROC and other plots were generated using the R computing environment (Non-Patent Document 49).

[0192] Results of Example 2 Patient Demographics. Table 5 summarizes the characteristics of the 148 patients, including 103 (70%) knee prostheses, 43 (29%) hip prostheses, and 2 (1%) shoulder prostheses. 44 patients (30%) were diagnosed with PJI, and 104 (70%) were diagnosed with aseptic prosthetic joint failure. Most patients (n = 102, 69%) underwent revision surgery, including 62 cases of aseptic failure and 40 cases of PJI.

[0193] Conventional Testing and Microbiology Performance. Diagnostic test performance is shown in Table 6. Synovial fluid leukocyte count demonstrated a sensitivity of 80%. However, 12 patients had elevated absolute or relative leukocyte counts due to aseptic conditions, including rheumatoid joint disease (n = 3), recurrent dislocation (n = 2), early postoperative state (n = 2), trauma (n = 2), crystal arthropathy (n = 1), periprosthetic fracture (n = 1), and crystal-associated metallosis (n = 1). There were 21 (48%) culture-negative PJIs. Significant microbial growth was documented in 23 (52%) patients with PJI, whereas formal contamination (i.e., nonsignificant growth) was detected in 8 patients with PJI and 19 patients with aseptic disorders. Table 7 summarizes the causative pathogens of PJI. A total of 23 culture-positive PJIs were caused by hypovirulent pathogens in 10 episodes (43%) and hypervirulent pathogens in 13 episodes (57%).

[0194] Synovial fluid D-lactate results. The optimal D-lactate cutoff value was calculated to be 1.263 mmol / L. The sensitivity and specificity of the D-lactate test were 86.4% and 81.7%, respectively (Table 6). In 19 cases of sterile lesions, D-lactate concentrations were elevated above the cutoff value, including 12 sterile cases with subthreshold white blood cell counts and differential white blood cell counts and 7 cases with uninterpretable cell counts due to underlying inflammatory conditions. In two false-positive D-lactate samples, contamination with pathogens from the skin flora was documented. D-lactate showed negative results in six patients diagnosed with PJI according to the applicable definition criteria. Of these, in two cases, the diagnosis of PJI was based on only one current criterion (elevated synovial fluid white blood cell count or positive histopathology), while in the remaining four cases, the diagnosis of PJI was based on multiple fulfilled criteria, including one case with a sinus tract. Mean D-lactate concentrations were significantly lower in sterile lesions than in PJI cases (p < 0.001). Commercially available D-lactate test kits require 50 μl of synovial fluid. Turnaround time for both tests was 30–45 minutes.

[0195] Comparison of synovial fluid D-lactate with white blood cell count. No significant differences were observed between any pairwise comparisons of AUC between the synovial fluid biomarkers investigated (AUC D-乳酸塩 vs. AUC WBC p=0.8; Figure 3). The distribution of D-lactate and white blood cell counts in PJI and sterile lesions is shown in Figure 4. In 12 sterile cases with nondiagnostic elevated white blood cell counts due to an underlying inflammatory condition, 7 had positive D-lactate results and 5 had negative D-lactate. Of these 12 patients, 11 underwent revision surgery, and ultimately, a complete diagnostic evaluation was performed in 6 of the 12, confirming sterile pathology.

[0196] In acute PJI, D-lactate and white blood cell count showed 100% sensitivity, whereas in chronic PJI, sensitivity decreased to 81% and 72%, respectively (p = 0.268). The performance of D-lactate and white blood cell count in early and late / late infections is shown in Figure 5. D-lactate showed higher sensitivity compared with white blood cell count, but white blood cell count was more specific for both groups. In patients presenting early after surgery, the tests showed similar sensitivity (67% vs. 58%; p = 0.572), whereas in the late / late setting, D-lactate was more sensitive (94% vs. 84%; p = 0.027).

[0197] Synovial fluid D-lactate concentrations and microbiology. In culture-negative PJIs, the mean D-lactate concentration was significantly lower than in culture-positive PJIs (0.915 mmol / L vs. 2.421 mmol / L; p = 0.004). The mean D-lactate concentration in culture-negative PJIs was significantly higher than in aseptically contaminated cases (0.915 mmol / L vs. 1.40 mmol / L; p < 0.001). No significant differences in D-lactate concentrations were observed when comparing PJIs caused by low- and high-virulence microorganisms (2.047 mmol / L vs. 2.586 mmol / L; p = 0.074) or early- and late-onset or late-stage infections (1.459 mmol / L vs. 1.217 mmol / L; p = 0.196).

[0198] Correlation between synovial fluid red blood cell and D-lactate concentrations. Positive correlations were observed between red blood cell and D-lactate overall (ρ = 0.185, p = 0.02) and in the aseptic subgroup (ρ = 0.339, p < 0.01). In the PJI subgroup, a negative correlation was observed but did not reach significance (ρ = -0.199, p = 0.195) (Figure 6). The difference between the aseptic and PJI subgroups was significant (p < 0.01).

[0199] Consideration of Example 2 In recent years, several biomarkers have been investigated as diagnostic tests for PJI (Non-Patent Documents 34, 35, 50). However, none have been exclusively evaluated for their ability to detect low-grade infections and early postoperative infections, which are difficult to distinguish from sterile conditions. The performance of diagnostic tests strongly depends on the definition criteria applied. Most studies have used the MSIS definition criteria (Non-Patent Document 51), which have a high threshold for confirming infection and therefore miss some low-grade infections (Non-Patent Document 44). In this study, we used criteria with a lower threshold for diagnosing PJI that also detect low-grade PJI (Non-Patent Documents 44, 52). In contrast to the MSIS criteria, CRP ESR is not considered as a diagnostic criterion for PJI because it provides little benefit in low-grade infections and is not specific for PJI (Non-Patent Document 33). Furthermore, leukocyte esterase is not included because it provides reliable results only in samples uncontaminated with blood (Non-Patent Document 50).

[0200] Late-onset infections are known to induce minimal clinical signs and symptoms, likely due to the low microbial load. As bacterial metabolism declines with biofilm maturation, detectable amounts of D-lactate are still produced. A statistically significant difference in D-lactate concentrations was observed between culture-negative PJI and sterile cases, supporting the etiology of sepsis in culture-negative specimens. Furthermore, D-lactate concentrations appear to be bacterial load-dependent, as they were higher in culture-positive than culture-negative PJI.

[0201] In this study, six patients with chronic PJI had false-negative synovial fluid D-lactate tests, two of which had positive cultures (one polymicrobial infection via a sinus tract and one coagulase-negative staphylococcus in the synovial fluid). Four of these patients also had normal synovial leukocyte counts, and three of these patients had infection confirmed only by positive periprosthetic histopathology. It remains unclear whether these cases are true PJI or overdiagnosed cases of PJI. One patient had a sinus tract, which has previously been described as altering diagnostic markers in synovial fluid due to constant drainage of inflammation. Although D-lactate production has been described for several bacterial species, including Staphylococcus species, Streptococcus species, Escherichia coli, Klebsiella pneumoniae, and Bacteroides fragilis, as well as Lactobacillales and intestinal flora (40, 42, 53), data on D-lactate production by other bacteria in body fluids are limited. According to our data and data in the literature (Non-Patent Document 41), the influence of bacterial toxicity on D-lactate concentration could not be estimated.

[0202] D-lactate concentrations were elevated above the cutoff value in 19 patients with sterile disorders. Based on the positive correlation between red blood cells and D-lactate in the sterile group, we hypothesize that false-positive D-lactate tests may occur due to the similar absorption wavelengths of hemoglobin, i.e., 540 nm for hemoglobin and 570 nm for D-lactate (Non-Patent Document 54). In PJI patients, the slightly negative correlation may be explained by a significant source of D-lactate from bacterial metabolism, where other factors cannot affect the concentration. We have not evaluated whether centrifugation of synovial fluid samples could improve the specificity of the D-lactate test.

[0203] In conclusion, synovial fluid D-lactate is an accurate diagnostic test for the diagnosis of PJI, comparable to synovial fluid leukocyte count. It requires only 50 μl of synovial fluid, has a short turnaround time, and is inexpensive. Modifications to the test could potentially improve its specificity, or it could be combined with a more specific confirmatory test.

[0204] Example 3: D-lactate measurement using a potentiometric electrochemical sensor Materials and Methods for Example 3 Biosensor fabrication. A potentiometric electrochemical sensor system was used. The system was constructed with three electrodes: a working / detecting electrode (a gold electrode obtained from Genefluidic, Inc., California, USA, with a φ2.5 mm sensing element), a platinum wire as a counter electrode, and an Ag / AgCl electrode (BASi) as a reference electrode.

[0205] The sensing layer of the working electrode was prepared as previously described (A polyaniline-based ultrasensitive potentiometric immunosensor for cardiac troponin complex detection. Qi Zhang, n, Alok Prabhu a, Avdar San a, Jafar F. Al-Sharab b, Kalle Levon, Biosensors and Bioelectronics 72 (2015) 100-106). The working electrode was coated with 20 μL of 1.5 wt% PANI / DNNSA dissolved in chloroform and dried in an oven at 60 °C for 2 h. The PANI / DNNSA-coated electrode was immersed in CP buffer (Sigma-Aldrich, Missouri, USA) containing 2.5 wt% glutaraldehyde (GA) as a cross-linking agent at room temperature for 1.5 h, followed by thorough rinsing with deionized water.

[0206] Enzyme immobilization. A commercially available kit for the determination of D-lactate was used. Reagent 1 (16 ml) contained D-lactate dehydrogenase ≥ 60 kU / l plus buffer pH 9.0, and Reagent 2 (4.5 ml) contained NAD + 50 μL of the reagent mixture was placed on the working electrode, which had been pretreated as previously described, overnight at 4°C for enzyme immobilization.

[0207] Preparation of D-lactate calibration samples: Lyophilized lithium D-lactate (Sigma-Aldrich, Missouri, USA) was diluted to different concentrations (0%, 25%, 50%, 75%, and 100%) in deionized water.

[0208] Electrochemical measurements. 100 μL of samples containing different concentrations of D-lactate were placed on the surface of the working electrode, and the voltage corresponding to the defined D-lactate concentration in the calibrated sample was measured at room temperature. Open-circuit potential measurements (OCP) were performed using a CHI660d electrochemical workstation (CH Instruments).

[0209] Results of Example 3 The measured concentrations and corresponding voltages for two independent experiments are shown in Figure 7 and Table 8. Using D-lactate concentrations below 1.2 mM, the voltage was below 85 mV (interpreted as a negative result), while concentrations above this cutoff value, determined by spectrophotometry, consistently showed voltage measurements above 85 mV.

[0210] Consideration of Example 3 The dose-response effect of the potentiometric electrochemical sensor-based method demonstrates proof of concept for spectrophotometrically independent measurements, independent of other components of biological samples (e.g., synovial fluid), such as red blood cells, which may have false-positive spectrophotometric results due to absorption wavelengths similar to those of hemoglobin. Therefore, the specificity of the potentiometric electrochemical sensor-based method of the present invention is higher than other currently available methods. This feature of the new test is important because false-positive results can lead to antibiotic and surgical overtreatment with adverse patient outcomes.

[0211] Example 4: D-lactate measurement using an amperometric electrochemical sensor Materials and Methods for Example 4 The inventors conducted studies using an amperometric electrochemical sensor comprising a test strip (chip) with a working electrode, a counter electrode, and a reference electrode on its surface, and an electrochemical potentiostat for measuring the electrical signal for electrochemical detection. The test strip can be combined with a small and portable electronic device for electrochemical detection.

[0212] Preparation of D-lactate calibration samples: Commercially available lyophilized sodium D-lactate (Sigma-Aldrich, MO, USA) was recovered from the lyophilizate by adding the necessary amount of deionized water to achieve final concentrations of 0.01 mM, 0.03 mM, 0.1 mM, 0.3 mM, 1.0 mM, 3.0 mM, 10.0 mM, and 30.0 mM.

[0213] Preparation of enzyme mixture. Commercially available lyophilized D-lactate dehydrogenase from Staphylococcus epidermidis (Sigma-Aldrich, MO, USA) was diluted in phosphate buffer to a final concentration of 100 U / ml. Commercially available lyophilized NAD free acid (Sigma-Aldrich, MO, USA) was diluted to a final concentration of 20 mmol / L. The reagents were dissolved in phosphate buffers with two different pH concentrations (pH 6.5 and pH 8.5).

[0214] Electrochemical measurements. Two experiments were performed using phosphate buffer solutions with different pHs (pH 6.5 and pH 8.5). 100 μL of a mixture containing phosphate buffer (pH 6.5 or pH 8.5), 10 U of D-LDH, 20 mmol / L NAD, and different concentrations of D-lactate was placed on the chip surface. Chronoamperometry with a standard potentiostat (CompactStat.h-Standard, Ivium Technologies, Eindhoven, The Netherlands) was used to measure the current corresponding to a defined D-lactate concentration in the calibrated sample at room temperature.

[0215] Results of Example 4 The measured concentrations of D-lactate in pH 6.5 phosphate buffer and the corresponding currents are shown in Figure 8 and Table 9. The measured concentrations of D-lactate in pH 8.5 phosphate buffer and the corresponding currents are shown in Figure 9 and Table 10. Using concentrations of D-lactate below 1.2 mM, the current was below 422 nA (interpreted as a negative result), while concentrations above this cutoff value, as determined by spectrophotometry, consistently showed current measurements above 422 nA.

[0216] Consideration of Example 4 The amperometric electrochemical sensor showed a dose-response effect when different concentrations of D-lactate were measured independently of the buffer pH used, demonstrating proof-of-concept for spectrophotometrically independent measurement of D-lactate. Furthermore, using a pH 8.5 phosphate buffer, we were able to detect D-lactate concentrations at higher currents, providing better sensitivity for the biosensor to detect D-lactate concentrations in unknown samples.

[0217] Example 5: D-lactate measurement in synovial fluid samples using an electrochemical sensor. Materials and Methods for Example 5 The inventors conduct their studies using a test strip (chip) with working, counter and reference electrodes on its surface for electrochemical detection, and an amperometric electrochemical sensor (biosensor) equipped with an electrochemical potentiostat for measurement of the electrical signal.

[0218] Synovial fluid samples. In this study, we use the synovial fluid samples obtained in Example 2. In this study cohort, 10 patients were diagnosed with periprosthetic joint infection (PJI). 30 patients were diagnosed with aseptic failure of the prosthetic joint (AF), 20 of which tested false positive in a previous study using spectrophotometry.

[0219] Preparation of enzyme mixture. Commercially available lyophilized D-lactate dehydrogenase from Staphylococcus epidermidis (Sigma-Aldrich, MO, USA) was diluted in phosphate buffer (pH 8.5) to a final concentration of 100 U / ml. Commercially available lyophilized NAD free acid (Sigma-Aldrich, MO, USA) was diluted in phosphate buffer (pH 8.5) to a final concentration of 20 mmol / L.

[0220] Electrochemical measurements. A 90 μL mixture containing phosphate buffer (pH 8.5), 10 U of d-LDH, 20 mmol / L NAD, and 10 μL of synovial fluid sample was placed on the chip surface. Current measurements were performed at room temperature using chronoamperometry with a standard potentiostat (CompactStat.h-Standard, Ivium Technologies, Eindhoven, The Netherlands).

[0221] Results of Example 5 Using electrochemical measurement of D-lactate as described herein, it was possible to identify all AF patients and distinguish them from PJI patients. All AF patients showed lower current measurements than PJI patients. Therefore, it is possible to use an appropriate (current) cutoff value that can identify PJI with very high specificity and sensitivity.

[0222] Discussion of Example 5 The amperometric electrochemical sensor exhibited excellent sensitivity and specificity in diagnosing PJI, demonstrating proof of concept for spectrophotometrically independent measurements. This method is independent of components of biological samples (e.g., synovial fluid), such as red blood cells, which may result in false-positive spectrophotometric results due to absorption wavelengths similar to those of hemoglobin. Therefore, the specificity of the electrochemical-based method of the present invention is higher than other currently available methods. This feature of the new test is important because false-positive results can lead to antibiotic and surgical overtreatment, with adverse patient outcomes.

[0223] In a planned embodiment, detection of the electrical signal will be performed using a battery-powered, handheld, compact reader similar to a glucometer (FreeStyle Precision Pro, Abbott, North Chicago, IL, USA), which is used to obtain quantitative information about the analyte.

[0224] (table) Table of Example 1 Table 1. Demographic data and characteristics of 224 patients with periprosthetic joints stratified by sterile and infectious pathology.

[0225] [Table 1] PJI-Periprosthetic joint infection, AF-Aseptic failure

[0226] Table 2. Microbiology of prosthetic joint infections.

[0227] [Table 2] 1 Candida parapsilosis (n=1), Corynebacterium species (n=1). 2 One patient with PJI had a mixed infection with Staphylococcus aureus and Streptococcus pyogenes.

[0228] Table 3. Analytical performance of synovial fluid tests.

[0229] [Table 3] PJI-periprosthetic joint infection, AF-aseptic failure, AUC-area under the curve, PPV-positive predictive value, NPV-negative predictive value, CI-confidence interval

[0230] Table of Example 2 Table 4. Periprosthetic joint infection is defined as meeting ≥1 criteria according to the European Society of Bone and Joint Infection (EBJIS) working definition.

[0231] [Table 4] 1 Acute inflammation was defined as 23 or more granulocytes per high-power field and corresponds to type II or III according to Krenn and Morawietz (55). 2 The leukocyte cutoff is not considered diagnostic within 6 weeks postoperatively in active rheumatoid arthropathy, periprosthetic fractures, joint trauma, or dislocations. 3 Periprosthetic tissue cultures were considered positive if highly pathogenic organisms grew in one or more specimens ( Staphylococcus aureus , Enterobacteriaceae , Streptococcus species, Candida species) or if low-virulence organisms grew in two or more specimens ( coagulase-negative staphylococci , enterococci , Cutibacterium [formerly known as Propionibacterium ] species, and other bacteria of the skin microbiome). 4 Sonication was considered positive if the sonication solution grew 1 CFU / ml or more of highly pathogenic organisms or 50 CFU / ml or more of low pathogenic organisms (Non-Patent Document 47).

[0232] Table 5. Patient characteristics

[0233] [Table 5]

[0234] Table 6. Performance of non-microbiological and microbiological tests according to the proposed EPJIC standards.

[0235] [Table 6-1] [Table 6-2] Note: If a denominator is indicated, testing was not performed in all patients. *PJI was confirmed if at least one of the following criteria was present: clinical features (i.e., presence of visible suppuration or sinus tracts in the synovial fluid or periprosthetic joint, elevated leukocyte count in the synovial fluid (>2000 leukocytes / μl or >70% granulocytes), histopathological evidence of inflammation in the periprosthetic tissue with significant microbiological positivity. 1 Eleven patients had visible suppuration of the synovial fluid, one had a sinus tract, and seven had both. 2 Twelve of 148 patients had an increased white blood cell count (n = 9) or granulocyte percentage (n = 8), but were not diagnosed with PJI because of concomitant crystal arthritis (n = 1), recurrent dislocation (n = 2), rheumatoid joint disease (n = 3), early postoperative state (n = 2), trauma (n = 2), periprosthetic fracture (n = 1), or metallosis with crystals (n = 1). 3 False-positive results were interpreted as positive for performance evaluation. In three cases, defined as uninterpretable, the white blood cell count and granulocyte percentage were not elevated above the cutoff values. 4 Growth of a low-virulence organism in only one specimen was insufficient for the diagnosis of PJI.

[0236] Table 7. Microorganisms isolated in 23 patients with culture-positive PJI.

[0237] [Table 7]

[0238] Table of Example 3 Table 8.

[0239] [Table 8] The mean voltage (mV) was calculated from two experiments. *Based on spectrophotometrically determined cutoff values

[0240] Table of Example 4 Table 9. Current measurements at pH 6.5.

[0241] [Table 9] The mean current (nA) was calculated from two experiments. * Based on spectrophotometrically determined cutoff values

[0242] Table 10. Current measurements at pH 8.5.

[0243] [Table 10] The mean current (nA) was calculated from two experiments. * Based on spectrophotometrically determined cutoff values

Claims

1. 1. An in vitro method for the diagnosis, prognosis, risk assessment, monitoring, treatment guidance and / or treatment control of an infectious disease, comprising: a. Providing a sample from a subject exhibiting clinical symptoms of infection and / or suspected of infection; b. determining the level of D-lactate in the sample; c. comparing the D-lactate level determined herein to a suitable control, or reference value, which is a sample from a healthy subject, and a level higher than the control or equal to or greater than the reference value serves as an indication of the presence of an infection; d. An in vitro method wherein the level of D-lactate in the sample is determined by an electrochemical sensing system (biosensor), wherein the electrochemical sensing system comprises a D-lactate binding molecule and the electrochemical sensing system comprises a potentiometric sensor.

2. 10. The in vitro method of claim 1, wherein the electrochemical sensing system comprises a transistor-based potentiometric sensor.

3. The in vitro method according to any one of claims 1 to 2, wherein the electrochemical sensing system comprises an ion-sensitive field effect transistor (ISFET).

4. The in vitro method of any one of claims 1 to 3, wherein the electrochemical sensing system comprises an amperometric sensor.

5. The in vitro method of any one of claims 1 to 4, wherein the electrochemical sensing system comprises D-lactate dehydrogenase (D-LDH).

6. The in vitro method of any one of claims 1 to 5, wherein the electrochemical sensing system comprises a detection (working) electrode.

7. The in vitro method of any one of claims 1 to 5, wherein the electrochemical sensing system comprises a detection (working) electrode comprising a carbon or gold surface.

8. 8. The in vitro method of claim 6 or 7, wherein a D-lactate binding molecule is immobilized on the detection electrode.

9. 8. The in vitro method of any one of claims 1 to 7, wherein the electrochemical sensing system comprises a disposable test strip (chip) for electrochemically determining D-lactate levels, wherein the test strip comprises a detection electrode having an immobilized D-lactate binding molecule.

10. 8. The in vitro method of any one of claims 1 to 7, wherein the electrochemical sensing system comprises a disposable test strip (chip) for electrochemically determining D-lactate levels, wherein the test strip comprises an immobilized D-lactate binding molecule and a detection electrode further having a counter electrode and / or a reference electrode.

11. 11. The in vitro method of claim 9 or 10, wherein the disposable test strip is placed into a battery-powered, handheld, compact reader for performing D-lactate measurements.

12. 12. The in vitro method according to any one of claims 1 to 11, wherein the immobilization of the D-lactate binding molecule, which is D-LDH, on the surface of the detection electrode is achieved by either adsorption, covalent binding, entrapment, encapsulation, cross-linking or thiol-gold interaction.

13. The in vitro method according to any one of claims 1 to 9, wherein the immobilization of the D-lactate binding molecule, which is D-LDH, on the surface of the detection electrode is achieved by cross-linking or thiol-gold interaction.

14. The in vitro method of any one of claims 1 to 13, wherein the electrochemical sensing system allows for the parallel determination of the level of D-lactate in two or more samples.

15. The in vitro method according to any one of claims 1 to 13, wherein the infection is a microbial, bacterial and / or fungal infection.

16. 15. The in vitro method according to any one of claims 1 to 14, wherein the infection is a microbial, bacterial and / or fungal infection having at least one infectious agent selected from the group consisting of Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus spp., Enterococcus spp., anaerobes, gram-negative bacteria and Candida spp.

17. 17. The in vitro method according to any one of claims 1 to 16, wherein the infection is a joint infection, a periprosthetic joint infection (PJI), meningitis, peritonitis, a pleural cavity infection, a pericardial cavity infection and / or a bloodstream infection.

18. 18. The in vitro method of any one of claims 1 to 17, wherein a current or voltage measurement by the electrochemical sensing system corresponding to a level of D-lactate in the sample of 0.4 mmol / L or greater indicates the presence of an infection.

19. 19. The in vitro method of any one of claims 1 to 18, wherein a current or voltage measurement by the electrochemical sensing system corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater indicates the presence of an infection and / or the need to initiate or change antibiotic treatment.

20. 20. The in vitro method of any one of claims 1 to 19, wherein the electrochemical sensing system is calibrated using one or more calibration samples of defined D-lactate concentrations prior to determining the level of D-lactate in the sample.

21. 21. The in vitro method of any one of claims 1 to 20, wherein the level of D-lactate determined by the electrochemical sensing system is not affected by the number of red blood cells and / or hemoglobin present in the sample.

22. 22. The in vitro method according to any one of claims 1 to 21, wherein the sample is selected from the group consisting of a body fluid sample, a homogenized tissue sample, a blood sample, a serum sample, a plasma sample, a urine sample, a joint aspirate, a synovial fluid sample, a peritoneal fluid sample, a pleural fluid sample, a pericardial fluid sample, and / or a cerebrospinal fluid sample.

23. A kit for carrying out the method according to any one of claims 1 to 22, comprising: an electrochemical sensing system (biosensor) for determining the level of D-lactate in the sample; and reference data; or A kit for carrying out the method according to any one of claims 1 to 22, comprising: an electrochemical sensing system (biosensor) for determining the level of D-lactate in the sample; Reference data; and a reagent for calibrating the electrochemical sensing system.

24. A kit for carrying out the method according to any one of claims 1 to 22, comprising the following A and B, or A, B and C: A 1. An electrochemical sensing system (biosensor) for determining the level of D-lactate in a sample, wherein: The electrochemical sensing system comprises: i. A test strip (chip) for electrochemically determining D-lactate levels, wherein the test strip comprises a detection electrode having an immobilized D-lactate binding molecule, and further comprises a counter electrode and / or a reference electrode; Or, The electrochemical sensing system comprises: i. A test strip (chip) for electrochemically determining D-lactate levels, wherein the test strip comprises a detection electrode having an immobilized D-lactate binding molecule, and further comprises a counter electrode and / or a reference electrode, and additionally comprises: ii. A handheld, compact reader for inserting the test strip and performing the D-lactate measurement; B Reference value data (also referred to as reference data) that is a reference level corresponding to a D-lactate level in the sample of 1.2 mmol / L or greater; Or, Reference value data (also referred to as reference data), which is a reference level corresponding to a level of D-lactate in the sample of 1.2 mmol / L or greater, the reference value data being stored on a computer-readable medium and / or used in the form of computer-executable code configured to compare the determined level of D-lactate to the reference value; C A reagent for calibrating the electrochemical sensing system.

25. An electrochemical sensing system for determining D-lactate levels in a sample, comprising D-LDH as a D-lactate recognition component immobilized on a test strip for insertion into a handheld reader.

Images